

05-23-00

A
SEE
BOX

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Attorney Docket No.: ISPH-0463

Inventors: Monia et al.

Title: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF RAS

"Express Mail" Label No. EL550128459US
Date of Deposit - May 22, 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By Jane Massey Licata
Typed Name: Jane Massey Licata

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

37 C.F.R. §1.53 TRANSMITTAL LETTER

This is a request for filing a continuation-in-part application under 35 U.S.C. 111(a) and 37 CFR 1.53(b), of pending prior application Serial No. 09/128,494, filed August 3, 1998, which is a continuation-in-part of prior application Serial No. 08/411,734, filed April 3, 1995, which is a continuation of PCT/US93/09346, filed October 1, 1993, which is a continuation-in-part of prior application Serial No. 07/958,134, filed October 5, 1992 and of 08/007,996, filed January 21, 1993.

APPLICATION ELEMENTS

1. (xx) Filing fee as calculated and transmitted as described below

- DEPARTMENT OF COMMERCE
2. (xx) Specification having 69 pages and including the following:
- a. (xx) Descriptive Title of the Invention
 - b. (xx) Cross References to Related Applications (if applicable)
 - c. () Statement Regarding Federally-Sponsored Research/Development (if applicable)
 - d. () Reference to Microfiche Appendix (if applicable)
 - e. (xx) Background of the Invention
 - f. (xx) Brief Summary of the Invention
 - g. (xx) Brief Description of the Drawings (if drawings filed)
 - h. (xx) Detailed Description
 - i. (xx) Claims(s) as Classified Below
 - j. (xx) Abstract of the Disclosure
3. (xx) Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. () Formal
 - b. (xx) Informal
- Number of Sheets 12
4. Oath or Declaration
- a. () Newly executed (original or copy) (xx) Unexecuted
 - b. () Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
 - c. (xx) With Power of Attorney () Without Power of Attorney
5. () Incorporation by Reference (usable if Box 4b is checked)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. Computer Program in Microfiche (Appendix)
7. (xx) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. (xx) Paper copy
 - b. (xx) Computer Readable copy (identical to computer copy)
 - c. (xx) Statement Verifying Identical Paper and computer Readable copy
 - d. () Request to Use Computer Readable Form from Another Application in accordance with 37 C.F.R. 1.821(e)

ACCOMPANYING APPLICATION PARTS

8. () Assignment Papers (cover sheet & document(s))
9. () 37 CFR 3,73(B) Statement (when there is an assignee)
10. () English Translation Document (if applicable)
11. () Information Disclosure Statement/PTO-1449
() copies of IDS citations
12. () Preliminary Amendment
13. (xx) Acknowledgment postcard
14. (xx) Certificate of Mailing
() First Class (xx) Express Mail Label No: **EL550128459US**
15. () Certified copy of Priority Document(s) (if foreign priority is claimed)
16. Additional Enclosures:
(xx) Verified Statement Claiming Small Entity Status
() Verified Statement Claiming Small Entity Status was filed in the parent case.
() Request to Use Computer Readable Form from Another Application in accordance with 37 C.F.R. 1.821(e)

- () A Petition for Extension of Time has been filed in the parent application, Serial No. _____ filed _____. A copy of the Petition for Extension of Time is enclosed.

FEE CALCULATION AND TRANSMITTAL

The filing fee is calculated below on the basis of claims as filed in the prior application, less any claims cancelled or including any claims added by amendment listed below:

			SMALL ENTITY			OTHER THAN SMALL ENTITY	
For:	No. Filed	No. Extra	Rate	Fee	OR	Rate	Fee
BASIC FEE							
Total Claims	23- 20 =	3	x \$9=	\$27	OR	x \$22=	\$
Indep. Claims	2- 3 =	0	x \$39=	\$0	OR	x \$82=	\$
First Presentation Multiple Dependent Claims			+\$135=	\$	OR	+\$270=	\$
TOTAL				\$372			\$

- () Please charge my Deposit Account No. 12-1086 in the amount of \$ _____. This sheet is attached in triplicate.
- (xx) A check in the amount of \$ 372.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 12-1086.
- (xx) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-1086. This sheet is attached in duplicate.
- (XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.

- 0022554-0957550
- (XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).
 - (XX) The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 12-1086. This sheet is attached in duplicate.
 - (XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).
 - () The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
 - (XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: May 22, 2000

Law Offices of
Jane Massey Licata
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

05/19/00 08:49 FAX 760 603 3820
05/18/00 THU 08:25 FAX 8588101454

ISIS PATENT GROUP
LAW OFFICES

→ LICATA

② 002

② 002

Page 1 of 2

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27 (c)) - SMALL BUSINESS CONCERN

Docket No.
ISPH-0463

Serial No.	Filing Date	Patent No.	Issue Date
Not yet assigned	Herewith		
Applicant/ Monia et al. Patentee:			
Invention: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF RAS			

I hereby declare that I am:

- the owner of the small business concern identified below.
 an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: Isis Pharmaceuticals, Inc.

ADDRESS OF CONCERN: 2292 Faraday Avenue, Carlsbad, CA 92008

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:

- the specification filed herewith with title as listed above.
 the application identified above.
 the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an Independent Inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

05/18/00 08:50 FAX 760 603 3820
05/18/00 THU 08:26 FAX 8568101454

ISIS PATENT GROUP
LAW OFFICES

→ LICATA

□ 003

□ 003

Page 2 of 2

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- no such person, concern or organization exists.
- each such person, concern or organization is listed below.

FULL NAME

ADDRESS

Individual Small Business Concern Nonprofit Organization

FULL NAME

ADDRESS

Individual Small Business Concern Nonprofit Organization

FULL NAME

ADDRESS

Individual Small Business Concern Nonprofit Organization

FULL NAME

ADDRESS

Individual Small Business Concern Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: B. Lynne Parshall


TITLE OF PERSON SIGNING: Executive Vice President

OTHER THAN OWNER: Isis Pharmaceuticals, Inc.

ADDRESS OF PERSON SIGNING: Carlsbad Research Center

2292 Faraday Avenue

Carlsbad, CA 92008

SIGNATURE:  DATE: 5/19/00

ANTISENSE OLIGONUCLEOTIDE INHIBITION OF RAS

This application is a continuation-in-part of U.S. Patent Application Serial No. 09/128,494 filed August 3, 1998 which is a continuation-in-part of U.S. Patent Application Serial No. 08/411,734, filed April 3, 1995 which is a continuation of PCT/US93/09346, filed October 1, 1993, which is a continuation-in-part of U.S. Patent Application Serial No. 07/958,134, filed October 5, 1992, and U.S. Patent Application Serial No. 08/007,996, filed January 21, 1993, all of which 10 are assigned to the assignee of the present invention and are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

This invention relates to compositions and methods for the inhibition of expression of ras, a naturally occurring 15 protein which occasionally converts to an activated form that has been implicated in tumor formation. Antisense oligonucleotides targeted to H-, Ki- and N-ras are provided. This invention is further directed to the detection of both normal and activated forms of the ras gene in cells and 20 tissues, and can form the basis for research reagents and kits both for research and diagnosis. Furthermore, this invention is directed to prevention and treatment of conditions associated with ras.

BACKGROUND OF THE INVENTION

25 Alterations in the cellular genes which directly or indirectly control cell growth and differentiation are considered to be the main cause of cancer. There are some thirty families of genes, called oncogenes, which are implicated in human tumor formation. Members of one such

family, the ras gene family, are frequently found to be mutated in human tumors. In their normal state, proteins produced by the ras genes are thought to be involved in normal cell growth and maturation. Mutation of the ras gene, causing 5 an amino acid alteration at one of three critical positions in the protein product, results in conversion to a form which is implicated in tumor formation. A gene having such a mutation is said to be "mutant" or "activated." Unmutated ras is called "wild-type" or "normal" ras. It is thought that 10 such a point mutation leading to ras activation can be induced by carcinogens or other environmental factors. Over 90% of pancreatic adenocarcinomas, about 50% of adenomas and adenocarcinomas of the colon, about 50% of adenocarcinomas of the lung and carcinomas of the thyroid, and a large fraction 15 of malignancies of the blood such as acute myeloid leukemia and myelodysplastic syndrome have been found to contain activated ras oncogenes. Overall, some 10 to 20% of human tumors have a mutation in one of the three ras genes (H-ras, Ki-ras, or N-ras).

20 It is presently believed that inhibiting expression of activated oncogenes in a particular tumor cell might force the cell back into more normal growth. For example, Feramisco et al., *Nature* 1985, 314, 639-642, demonstrated that if cells transformed to a malignant state with an activated ras gene 25 are microinjected with antibody which binds to the protein product of the ras gene, the cells slow their rate of proliferation and adopt a more normal appearance. This has been interpreted as support for the involvement of the product of the activated ras gene in the uncontrolled growth typical 30 of cancer cells.

There is a great desire to provide compositions of matter which can modulate the expression of ras, and particularly to provide compositions of matter which specifically modulate the expression of activated ras. It is greatly desired to provide 35 methods of diagnosis and detection of nucleic acids encoding

ras in animals. It is also desired to provide methods of diagnosis and treatment of conditions arising from ras activation. In addition, improved research kits and reagents for detection and study of nucleic acids encoding ras are
5 desired.

Inhibition of oncogene expression has been accomplished using retroviral vectors or plasmid vectors which express a 2-kilobase segment of the Ki-ras protooncogene RNA in antisense orientation. Mukhopadhyay, T. et al. (1991) *Cancer Research* 51, 1744-1748; PCT Patent Application PCT/US92/01852
10 (WO 92/15680); Georges, R.N. et al. (1993) *Cancer Research*, 53, 1743-1746.

Antisense oligonucleotide inhibition of oncogenes has proven to be a useful tool in understanding the roles of
15 various oncogene families. Antisense oligonucleotides are small oligonucleotides which are complementary to the "sense" or coding strand of a given gene, and as a result are also complementary to, and thus able to stably and specifically hybridize with, the mRNA transcript of the gene. Holt et al.,
20 *Mol. Cell Biol.* 1988, 8, 963-973, have shown that antisense oligonucleotides hybridizing specifically with mRNA transcripts of the oncogene c-myc, when added to cultured HL60 leukemic cells, inhibit proliferation and induce differentiation. Anfossi et al., *Proc. Natl. Acad. Sci.* 1989,
25 86, 3379-3383, have shown that antisense oligonucleotides specifically hybridizing with mRNA transcripts of the c-myb oncogene inhibit proliferation of human myeloid leukemia cell lines. Wickstrom et al., *Proc. Nat. Acad. Sci.* 1988, 85, 1028-1032, have shown that expression of the protein product
30 of the c-myc oncogene as well as proliferation of HL60 cultured leukemic cells are inhibited by antisense oligonucleotides hybridizing specifically with c-myc mRNA. United States Patent No: 4,871,838 (Bos et al.) discloses oligonucleotides complementary to a mutation in codon 13 of

N-ras to detect said mutation. United States Patent No: 4,871,838 (Bos et al.) discloses molecules useful as probes for detecting a mutation in DNA which encodes a ras protein.

In all these cases, instability of unmodified oligonucleotides has been a major problem, as they are subject to degradation by cellular enzymes. PCT/US88/01024 (Zon et al.) discloses phosphorothioate oligonucleotides hybridizable to the translation initiation region of the amplified c-myc oncogene to inhibit HL-60 leukemia cell growth and DNA synthesis in these cells. Tidd et al., *Anti-Cancer Drug Design* 1988, 3, 117-127, evaluated methylphosphonate antisense oligonucleotides hybridizing specifically to the activated N-ras oncogene and found that while they were resistant to biochemical degradation and were nontoxic in cultured human HT29 cells, they did not inhibit N-ras gene expression and had no effect on these cells. Chang et al. showed that both methylphosphonate and phosphorothioate oligonucleotides hybridizing specifically to mRNA transcripts of the mouse Balb-ras gene could inhibit translation of the protein product of this gene *in vitro*. Chang et al., *Anti-Cancer Drug Design* 1989, 4, 221-232; Brown et al., *Oncogene Research* 1989, 4, 243-252. It was noted that T_m was not well correlated with antisense activity of these oligonucleotides against *in vitro* translation of the ras p21 protein product. Because the antisense oligonucleotides used by Chang et al. hybridize specifically with the translation initiation region of the ras gene, they are not expected to show any selectivity for activated ras and the binding ability of these oligonucleotides to normal (wild-type) vs. mutated (activated) ras genes was not compared.

Helene and co-workers have demonstrated selective inhibition of activated (codon 12 G→T transition) H-ras mRNA expression using a 9-mer phosphodiester linked to an acridine intercalating agent and/or a hydrophobic tail. This compound displayed selective targeting of mutant ras message in both

Rnase H and cell proliferation assays at low micromolar concentrations. Saison-Behmoaras, T. et al., *EMBO J.* 1991, 10, 1111-1118. Chang and co-workers disclose selective targeting of mutant H-ras message; this time the target was 5 H-ras codon 61 containing an A→T transversion and the oligonucleotide employed was either an 11-mer methylphosphonate or its psoralen derivative. These compounds, which required concentrations of 7.5-150 μM for activity, were shown by immunoprecipitation to selectively 10 inhibit mutant H-ras p21 expression relative to normal p21. Chang et al., *Biochemistry* 1991, 30, 8283-8286.

SUMMARY OF THE INVENTION

The present invention relates to antisense oligonucleotides which are targeted to human ras, and methods 15 of using them. More specifically, the present invention provides oligonucleotides which are targeted to mRNA encoding human H-ras, Ki-ras and N-ras and which are capable of inhibiting ras expression. Oligonucleotides targeted to a 5' untranslated region, translation initiation site, coding 20 region or 3' untranslated region of human N-ras are provided. Methods of modulating ras expression, of inhibiting the proliferation of cancer cells and of treating conditions associated with ras are provided. These methods employ the oligonucleotides of the invention.

25 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a series of 8 panels (Fig. 1a-1h) showing inhibition of ras in a dose-dependent manner. Solid lines are activity against wild-type (normal) ras, dotted lines show activity against activated (mutant) ras.

Figure 2 is a bar graph showing antisense activities of a uniform deoxy phosphorothioate and shortened chimeric oligonucleotides against ras-luciferase.

Figure 3 is a line graph showing correlation between antisense activity and ability to activate RNase H as a function of deoxy gap length using phosphorothioate 2'-O-methyl oligonucleotides targeted against ras.

Figure 4 is a line graph showing anti-tumor activity of ISIS 2503 against A549 human cell tumors in nude mice.

Figure 5 is a line graph showing anti-tumor activity of ras oligo ISIS 2503, administered with cationic lipid, against A549 human cell tumors in nude mice.

Figure 6 is a bar graph showing antisense inhibition of Ki-ras mRNA expression in three human colon carcinoma cell lines, Calu1, SW480 and SW620.

Figure 7 is a bar graph showing inhibition of SW480 human carcinoma cell line proliferation by Ki-ras specific oligonucleotides ISIS 6957 and ISIS 6958.

Figure 8 is a bar graph showing reduction of H-ras mRNA levels by 2'-MOE analogs of ISIS 2503 (SEQ ID NO: 2). Black bars: 150 nM oligonucleotide dose; Diagonal hatched bars: 50 nM dose; horizontal hatched bars: 15 nM dose.

Figure 9 is a bar graph showing reduction of H-ras mRNA levels by MMI analogs of ISIS 2503 (SEQ ID NO: 2). Black bars: 500 nM oligonucleotide dose; Diagonal hatched bars: 100 nM dose; horizontal hatched bars: 50 nM dose.

Figure 10 is a bar graph showing reduction of N-ras mRNA levels by oligonucleotides 14686-14694, 14677 and 14678. Black bars: 400 nM oligonucleotide dose; Diagonal hatched bars: 200 nM dose; horizontal hatched bars: 100 nM dose.

DETAILED DESCRIPTION OF THE INVENTION

Malignant tumors develop through a series of stepwise, progressive changes that lead to the loss of growth control characteristic of cancer cells, i.e., continuous unregulated

proliferation, the ability to invade surrounding tissues, and the ability to metastasize to different organ sites. Carefully controlled *in vitro* studies have helped define the factors that characterize the growth of normal and neoplastic 5 cells and have led to the identification of specific proteins that control cell growth and differentiation. In addition, the ability to study cell transformation in carefully controlled, quantitative *in vitro* assays has led to the identification of specific genes capable of inducing the 10 transformed cell phenotype. Such cancer-causing genes, or oncogenes, are believed to acquire transformation-inducing properties through mutations leading to changes in the regulation of expression of their protein products. In some cases such changes occur in non-coding DNA regulatory domains, 15 such as promoters and enhancers, leading to alterations in the transcriptional activity of oncogenes, resulting in over- or under-expression of their gene products. In other cases, gene mutations occur within the coding regions of oncogenes, leading to the production of altered gene products that are 20 inactive, overactive, or exhibit an activity that is different from the normal (wild-type) gene product.

To date, more than 30 cellular oncogene families have been identified. These genes can be categorized on the basis of both their subcellular location and the putative mechanism 25 of action of their protein products. The ras oncogenes are members of a gene family which encode related proteins that are localized to the inner face of the plasma membrane. ras proteins have been shown to be highly conserved at the amino acid level, to bind GTP with high affinity and specificity, 30 and to possess GTPase activity. Although the cellular function of ras gene products is unknown, their biochemical properties, along with their significant sequence homology with a class of signal-transducing proteins known as GTP binding proteins, or G proteins, suggest that ras gene 35 products play a fundamental role in basic cellular regulatory

functions relating to the transduction of extracellular signals across plasma membranes.

Three ras genes, designated H-ras, Ki-ras, and N-ras, have been identified in the mammalian genome. Mammalian ras genes acquire transformation-inducing properties by single point mutations within their coding sequences. Mutations in naturally occurring ras oncogenes have been localized to codons 12, 13, and 61. The sequences of H-ras, Ki-ras and N-ras are known. Capon et al., *Nature* 302 1983, 33-37; Kahn et al., *Anticancer Res.* 1987, 7, 639-652; Hall and Brown, *Nucleic Acids Res.* 1985, 13, 5255-5268. The most commonly detected activating ras mutation found in human tumors is in codon 12 of the H-ras gene in which a base change from GGC to GTC results in a glycine-to-valine substitution in the GTPase regulatory domain of the ras protein product. Tabin, C.J. et al., *Nature* 1982, 300, 143-149; Reddy, P.E. et al., *Nature* 1982, 300, 149-152; Taparowsky, E. et al., *Nature* 1982, 300, 762-765. This single amino acid change is thought to abolish normal control of ras protein function, thereby converting a normally regulated cell protein to one that is continuously active. It is believed that such deregulation of normal ras protein function is responsible for the transformation from normal to malignant growth. It is therefore believed that inhibition of ras expression is useful in treatment and/or prevention of malignant conditions, i.e., cancer and other hyperproliferative conditions.

The H-ras gene has recently been implicated in a serious cardiac arrhythmia called long Q-T syndrome, a hereditary condition which often causes sudden death if treatment is not given immediately. Frequently, there are no symptoms prior to the onset of the erratic heartbeat. Whether the H-ras gene is precisely responsible for long Q-T syndrome is unclear. However, there is an extremely high correlation between inheritance of this syndrome and the presence of a particular

variant of the chromosome 11 region surrounding the H-ras gene. Therefore, the H-ras gene is a useful indicator of increased risk of sudden cardiac death due to the long Q-T syndrome.

5 N-ras was first identified as an oncogene in gene transfer experiments. Hall et al. *Nature* 1983, 303: 396-400. Its activation was characterized by Taparowsky et al. *Cell* 1983 34: 581-6. Activated N-ras is found in many hematologic neoplasms and solid tumors, suggesting a role for N-ras in the 10 development or maintenance of hyperproliferative conditions.

The present invention provides oligonucleotides for inhibition of human ras gene expression. Such oligonucleotides specifically hybridize with selected DNA or mRNA deriving from a human ras gene. The invention also 15 provides oligonucleotides for selective inhibition of expression of the mutant form of ras. This relationship between an oligonucleotide and its complementary nucleic acid target to which it hybridizes is commonly referred to as "antisense". "Targeting" an oligonucleotide to a chosen 20 nucleic acid target, in the context of this invention, is a multistep process. The process usually begins with identifying a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA made from the gene) whose expression is associated with a 25 particular disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the target is a nucleic acid encoding ras; in other words, the ras gene or mRNA expressed from the ras gene. The targeting process also includes determination of a site or sites within the nucleic 30 acid sequence for the oligonucleotide interaction to occur such that the desired effect- modulation of gene expression- will result. Once the target site or sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well

and with sufficient specificity, to give the desired modulation.

In the context of this invention "modulation" means either inhibition or stimulation. Inhibition of ras gene expression is presently the preferred form of modulation. This modulation can be measured in ways which are routine in the art, for example by Northern blot assay of mRNA expression or Western blot assay of protein expression as taught in the examples of the instant application. Effects on cell proliferation or tumor cell growth can also be measured, as taught in the examples of the instant application. "Hybridization", in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them. "Specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment or, in the case of *in vitro* assays, under conditions in which the assays are conducted.

0023504552660

In preferred embodiments of this invention, oligonucleotides are provided which are targeted to mRNA encoding H-ras, Ki-ras or N-ras. In accordance with this invention, persons of ordinary skill in the art will understand that mRNA includes not only the coding region which carries the information to encode a protein using the three letter genetic code, including the translation start and stop codons, but also associated ribonucleotides which form a region known to such persons as the 5'-untranslated region, 10 the 3'-untranslated region, the 5' cap region, intron regions and intron/exon or splice junction ribonucleotides. Thus, oligonucleotides may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the coding 15 ribonucleotides. In preferred embodiments, the oligonucleotide is targeted to a translation initiation site (AUG codon) or sequences in the coding region, 5' untranslated region or 3'-untranslated region of the ras mRNA. The functions of messenger RNA to be interfered with include all 20 vital functions such as translocation of the RNA to the site for protein translation, actual translation of protein from the RNA, splicing or maturation of the RNA and possibly even independent catalytic activity which may be engaged in by the RNA. The overall effect of such interference with the RNA 25 function is to cause interference with ras protein expression.

The present invention provides oligonucleotides for modulation of ras gene expression. Such oligonucleotides are targeted to nucleic acids encoding ras. As hereinbefore defined, "modulation" means either inhibition or stimulation. 30 Inhibition of ras gene expression is presently the preferred form of modulation.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of nucleotide or nucleoside monomers consisting of naturally 35 occurring bases, sugars and intersugar (backbone) linkages.

The term "oligonucleotide" also includes oligomers comprising non-naturally occurring monomers, or portions thereof, which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because 5 of properties such as, for example, enhanced cellular uptake and increased stability in the presence of nucleases.

Certain preferred oligonucleotides of this invention are chimeric oligonucleotides. "Chimeric oligonucleotides" or "chimeras", in the context of this invention, are 10 oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease 15 resistance, increased uptake into cells, increased binding affinity for the RNA target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of 20 RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligos are used, compared to phosphorothioate 25 deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. In one preferred embodiment, a chimeric oligonucleotide comprises at least one 30 region modified to increase target binding affinity, and, usually, a region that acts as a substrate for RNase H. Affinity of an oligonucleotide for its target (in this case, a nucleic acid encoding ras) is routinely determined by measuring the T_m of an oligonucleotide/target pair, which is 35 the temperature at which the oligonucleotide and target

dissociate; dissociation is detected spectrophotometrically. The higher the T_m, the greater the affinity of the oligonucleotide for the target. In a more preferred embodiment, the region of the oligonucleotide which is 5 modified to increase ras mRNA binding affinity comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides 10 have been shown to have a higher T_m (i.e., higher target binding affinity) than 2'-deoxyoligonucleotides against a given target. The effect of such increased affinity is to greatly enhance antisense oligonucleotide inhibition of ras gene expression. RNase H is a cellular endonuclease that 15 cleaves the RNA strand of RNA:DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of antisense inhibition. Cleavage of the RNA target can be routinely demonstrated by gel electrophoresis. In another preferred 20 embodiment, the chimeric oligonucleotide is also modified to enhance nuclease resistance. Cells contain a variety of exo- and endo-nucleases which can degrade nucleic acids. A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more 25 resistant to nuclease digestion than the native oligodeoxynucleotide. Nuclease resistance is routinely measured by incubating oligonucleotides with cellular extracts or isolated nuclease solutions and measuring the extent of intact oligonucleotide remaining over time, usually by gel 30 electrophoresis. Oligonucleotides which have been modified to enhance their nuclease resistance survive intact for a longer time than unmodified oligonucleotides. A variety of oligonucleotide modifications have been demonstrated to enhance or confer nuclease resistance. Oligonucleotides which 35 contain at least one phosphorothioate modification are

presently more preferred. In some cases, oligonucleotide modifications which enhance target binding affinity are also, independently, able to enhance nuclease resistance. A discussion of antisense oligonucleotides and some desirable 5 modifications can be found in De Mesmaeker et al. *Acc. Chem. Res.* 1995, 28:366-374.

Specific examples of some preferred oligonucleotides envisioned for this invention include those containing modified backbones, for example, phosphorothioates, 10 phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly $\text{CH}_2\text{-NH-O-CH}_2$, $\text{CH}_2\text{-}15 \text{N(CH}_3\text{)-O-CH}_2$ [known as a methylene(methylimino) or MMI backbone], $\text{CH}_2\text{-O-N(CH}_3\text{)-CH}_2$, $\text{CH}_2\text{-N(CH}_3\text{)-N(CH}_3\text{)-CH}_2$ and $\text{O-N(CH}_3\text{)-CH}_2\text{-CH}_2$ backbones, wherein the native phosphodiester backbone is represented as O-P-O-CH_2). The amide backbones disclosed by De Mesmaeker et al. *Acc. Chem. Res.* 1995, 28:366-374) are 20 also preferred. Also preferred are oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Patent 5,034,506). In other preferred embodiments, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide 25 backbone, the nucleobases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al. *Science* 1991, 254, 1497). Oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' 30 position: OH, SH, SCH₃, F, OCN, OCH₃OCH₃, OCH₃O(CH₂)_nCH₃, O(CH₂)_nNH₂ or O(CH₂)_nCH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; 35 heterocycloalkyl; heterocycloalkaryl; aminoalkylamino;

polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an 5 oligonucleotide and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy [2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl)] (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486). Other preferred modifications include 2'-methoxy (2'-O-10 CH₃), 2'-propoxy (2'-OCH₂CH₂CH₃) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics 15 such as cyclobutyls in place of the pentofuranosyl group.

Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include adenine (A), 20 guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2'deoxyctosine 25 and often referred to in the art as 5-me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalkylamino)adenine or other heterosubstituted 30 alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N⁶(6-aminohexyl)adenine and 2,6-diaminopurine. Kornberg, A., *DNA Replication*, W.H. Freeman & Co., San Francisco, 1980, pp75-77; Gebeyehu, G., et al. *Nucl. Acids Res.* 1987, 15:4513). A 35 "universal" base known in the art, e.g., inosine, may be

included. 5-me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., in Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and 5 are presently preferred base substitutions.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties 10 include but are not limited to lipid moieties such as a cholesterol moiety, a cholestryl moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA 1989, 86, 6553), cholic acid (Manoharan et al. Bioorg. Med. Chem. Let. 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al. Ann. 15 N.Y. Acad. Sci. 1992, 660, 306; Manoharan et al. Bioorg. Med. Chem. Let. 1993, 3, 2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res. 1992, 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al. EMBO J. 1991, 10, 111; Kabanov et al. FEBS Lett. 1990, 259, 20 327; Svinarchuk et al. Biochimie 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al. Tetrahedron Lett. 1995, 36, 3651; Shea et al. Nucl. Acids Res. 1990, 18, 3777), a 25 polyamine or a polyethylene glycol chain (Manoharan et al. Nucleosides & Nucleotides 1995, 14, 969), or adamantan acetic acid (Manoharan et al. Tetrahedron Lett. 1995, 36, 3651). Oligonucleotides comprising lipophilic moieties, and methods 30 for preparing such oligonucleotides are known in the art, for example, U.S. Patents 5,138,045, 5,218,105 and 5,459,255.

The oligonucleotides of the invention may be provided as prodrugs, which comprise one or more moieties which are cleaved off, generally in the body, to yield an active

oligonucleotide. One example of a prodrug approach is described by Imbach et al. in WO Publication 94/26764.

It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide. The present invention also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other modified oligonucleotides such as cholesterol-modified oligonucleotides.

The oligonucleotides in accordance with this invention preferably comprise from about 8 to about 50 nucleic acid base units. In the context of this invention it is understood that this encompasses non-naturally occurring oligomers as hereinbefore described, having 8 to 50 monomers.

The oligonucleotides of this invention can be used in diagnostics, therapeutics and as research reagents and kits. Since the oligonucleotides of this invention hybridize to the ras gene, sandwich and other assays can easily be constructed to exploit this fact. Furthermore, since the oligonucleotides

of this invention hybridize preferentially to the mutant (activated) form of the ras oncogene, such assays can be devised for screening of cells and tissues for ras conversion from wild-type to activated form. Such assays can be utilized 5 for differential diagnosis of morphologically similar tumors, and for detection of increased risk of cancer stemming from ras gene activation. Provision of means for detecting hybridization of oligonucleotide with the ras gene can routinely be accomplished. Such provision may include enzyme 10 conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of nucleic acids encoding ras or activated ras may also be prepared.

The following specific descriptions serve to illustrate 15 the invention and are not intended to limit the scope of the invention:

Antisense Oligonucleotide Inhibition of ras-Luciferase

Gene Expression: A series of antisense phosphorothioate oligonucleotides targeted to either the H-ras translation 20 initiation codon or the codon-12 point mutation of activated H-ras were screened using the ras-luciferase reporter gene system described in Examples 2-5. Of this initial series, six oligonucleotides were identified that gave significant and reproducible inhibition of ras-luciferase activity. The base 25 sequences, sequence reference numbers and SEQ ID numbers of these oligonucleotides (all are phosphorothioates) are shown in Table 1.

TABLE 1

OLIGO	SEQUENCE	SEQ ID NO:
5	2502 CTT-ATA-TTC-CGT-CAT-CGC-TC	1
	2503 TCC-GTC-ATC-GCT-CCT-CAG-GG	2
	2570 CCA-CAC-CGA-CGG-CGC-CC	3
	2571 CCC-ACA-CCG-ACG-GCG-CCC-A	4
	2566 GCC-CAC-ACC-GAC-GGC-GCC-CAC	5
	2560 TGC-CCA-CAC-CGA-CGG-CGC-CCA-CC	6

10 A dose-response experiment was performed in which cells expressing either the normal ras-luciferase reporter gene or the mutant ras-luciferase reporter gene were treated with increasing concentrations of the phosphorothioate oligonucleotide 2503 (SEQ ID NO: 2). This compound is
15 targeted to the translational initiation codon of H-ras RNA transcripts. Treatment of cells with this oligonucleotide resulted in a dose-dependent inhibition of ras-luciferase activity, displaying IC₅₀ values of approximately 50 nM for both the normal and the mutant ras targets. The observation
20 that an oligonucleotide targeted to the ras translation initiation codon is equally effective in reducing both mutant and normal ras expression is expected since the two targets have identical sequence compositions in the region surrounding the AUG translation initiation site.

25 Another dose-response experiment was performed in which cells were treated with phosphorothioate oligonucleotide 2570 (SEQ ID NO: 3), a compound that is targeted to the codon-12 point mutation of mutant (activated) H-ras RNA. Treatment of cells with increasing concentrations of this oligonucleotide
30 resulted in a dose-dependent inhibition of ras-luciferase activity in cells expressing either the mutant form or the normal form of ras-luciferase. However, oligonucleotide 2570 displayed approximately threefold selectivity toward the

mutant form of ras-luciferase as compared to the normal form. In fact, 2570 displayed an IC₅₀ value for the mutant form of ras-luciferase of approximately 100 nM whereas the same compound displayed an IC₅₀ value of approximately 250 nM for 5 the unmutated form.

Cells expressing either the normal form or the mutant form of ras-luciferase were treated with a single dose (0.5μM) of oligonucleotide targeted to either the translation initiation codon of H-ras or the codon-12 point mutation. The 10 antisense phosphorothioate oligonucleotides tested are shown in Table 1. Compound 2503 (SEQ ID NO: 2), targeted to the ras translational initiation codon, was most effective in inhibiting ras-luciferase activity, giving approximately 80% inhibition of both normal and mutant targets. ISIS 2502 gave 15 30-35% inhibition of both targets. Of the three compounds targeted to the codon-12 point mutation of activated H-ras, only the 17-mer oligonucleotide 2570 (SEQ ID NO: 3) displayed selectivity toward the mutated form of ras-luciferase as compared to the normal form, giving approximately 22% 20 inhibition of the normal target and 68% inhibition of the mutant target. ISIS 2571 gave approximately 60% inhibition of both targets and ISIS 2566 gave 65-70% inhibition of both targets. Table 2 summarizes data obtained with all 13 antisense oligonucleotides targeted to H-ras. A scrambled 25 control oligonucleotide gave no inhibition of either mutant or normal ras and a control oligonucleotide (ISIS 2907; SEQ ID NO: 19) complementary to the codon-12 region of normal ras gave 70% inhibition of the normal target but had no effect on the mutant ras. Shown for each oligonucleotide is its 30 sequence, region to which it is complementary, and its activity in suppressing expression of the ras-luciferase fusion protein (given as IC₅₀, the concentration in nM necessary to give 50% inhibition of ras-luciferase expression). The longer phosphorothioates targeted to the 35 codon-12 point mutation, while displaying substantial

antisense activity toward ras-luciferase expression, did not demonstrate selective inhibition of expression of the mutant form of ras-luciferase. Phosphorothioate oligonucleotides targeted to the codon-12 point mutation that were less than 17 nucleotides in length did not show activity to either form of ras-luciferase. These results demonstrate effective antisense activity of phosphorothioate oligonucleotides targeted to ras sequences.

Antisense oligonucleotides specifically hybridizable
10 with the H-ras AUG: Three 20-base phosphorothioate
oligonucleotides, targeted to the H-ras AUG codon, were
compared for their ability to inhibit ras-luciferase
expression in transient transfection assays as described in
Examples 2-5. These oligonucleotides, ISIS 2502 (SEQ ID NO:
15 1), 2503 (SEQ ID NO: 2) and 6186 (SEQ ID NO: 7) shown in Table
2, were tested for inhibition of ras-luciferase expression at
a single dose (100 nM) in HeLa cells. All three AUG-targeted
oligonucleotides were effective in inhibiting ras-luciferase
expression. These three phosphorothioate oligonucleotides
20 were also prepared with a 2'-O-methyl modification on each
sugar. The 2'-O-methylated version of ISIS 2503 (SEQ ID NO:
2) also inhibited ras-luciferase expression with an IC50
between 200 and 500 nM. SEQ ID NO: 7 as a 2'-O-methyl gave
approximately 40% inhibition at the highest dose (500 nM).

25

TABLE 2

Antisense oligonucleotides targeted to mutant H-ras
(Oligonucleotide sequences shown 5' to 3')

ISIS#	TARGET	SEQUENCE	IC50 (nM)	SEQ. ID NO.
2502	AUG	CTTATATTCCGTATCGCTC	750	1
2503	AUG	TCCGTCATCGCTCCTCAGGG	50	2
6186	AUG	TATTCCCGTATCGCTCCTCA	--	7
2563	CODON 12	CGACG	--	8

	2564	CODON 12	CCGACGG	--	9
	2565	CODON 12	ACCGACGGC	--	10
	2567	CODON 12	CACCGACGGCG	--	11
	2568	CODON 12	ACACCGACGGCGC	--	12
5	2569	CODON 12	CACACCGACGGCGCC	--	13
	3426	CODON 12	CCACACCGACGGCGCC	--	14
	3427	CODON 12	CACACCGACGGCGCCC	--	15
	2570	CODON 12	CCACACCGACGGCGGCC	100	3
	3428	CODON 12	CCCACACCGACGGCGCCC	--	16
	3429	CODON 12	CCACACCGACGGCGCCCA	--	17
	2571	CODON 12	CCCACACCGACGGCGCCCA	250	4
	2566	CODON 12	GCCCCACACCGACGGCGCCCAC	250	5
10	2560	CODON 12	TGCCCCACACCGACGGCGCCCACC	750	6
	2561	CODON 12	TTGCCCCACACCGACGGCGCCCACCA	1000	18
	2907	CODON 12 (normal)	CCACACCGCCGGCGCCC	--	19

Oligonucleotide length affects antisense activity and specificity: Oligonucleotides targeted to the H-ras codon- 12 point mutation also were effective in inhibiting expression of ras-luciferase. A series of eleven phosphorothioate 20 oligonucleotides, ranging in length between 5 and 25 bases, were made and tested for ability to inhibit mutant and wild type ras-luciferase in transient transfection assays as described in Examples 2-5. The oligonucleotides are shown in Table 2. At 100 nM oligonucleotide concentration, 25 oligonucleotides 15 bases or greater in length were found to inhibit expression of the mutant H-ras target. Selective inhibition of mutant over wild type ras-luciferase expression was observed for oligonucleotides between 15 and 19 bases in length. The maximum selectivity observed for inhibition of 30 mutant ras-luciferase relative to wild type was for the 17-mer 2570 (SEQ ID NO: 3) and was approximately 4-fold. In order

042250-145557552

to demonstrate that 2570 was acting in a sequence-specific manner, a variant of this compound was tested (2907; SEQ ID NO: 19) in which the central adenosine residue was replaced with cytosine, making this oligonucleotide perfectly complementary to the normal H-ras target. Hence, this oligonucleotide will contain a single mismatch at the center of the oligonucleotide/RNA duplex when fully hybridized to the mutant H-ras sequence. Oligonucleotide 2907 selectively inhibited expression of normal ras-luciferase (88% inhibition) relative to mutant ras-luciferase (5% inhibition).

Two 16-mers and two 18-mers complementary to the mutant codon-12 region (Table 2) were tested as described in Examples 2-5. Figure 1 shows the results of an experiment in which antisense activity and mutant selectivity was determined for 15 oligonucleotides of length 13, 15, 16, 17, 18 and 19 bases in a dose-dependent manner. The results obtained with these oligonucleotides demonstrated that the compounds that were active against mutant H-ras sequences also showed selectivity; oligonucleotides of length 16 (SEQ ID NO: 14 and SEQ ID NO: 15) and 17 bases (SEQ ID NO: 3) displayed the greatest selectivity (4- and 5-fold, respectively). The 13 base compound, 2568 (SEQ ID NO: 12), did not display antisense activity at any of the tested concentrations.

Chimeric 2'-O-methyl oligonucleotides with deoxy gaps:

Based on the sequence of the mutant-selective 17-mer (2570), a series of chimeric phosphorothioate 2'-O-methyl oligonucleotides were synthesized in which the end regions consisted of 2'-O-methyl nucleosides and the central residues formed a "deoxy gap". The number of deoxy residues ranged 30 from zero (full 2'-O-methyl) to 17 (full deoxy). These oligonucleotides are shown in Table 3.

TABLE 3

Chimeric phosphorothioate oligonucleotides
having 2'-O-methyl ends (**bold**) and central deoxy gap
(Mutant codon-12 target)

	OLIGO	# DEOXY	SEQUENCE	SEQ ID NO:
5	4122	0	CCACACC GACGGCGCCC	3
	3975	1	CCACACC GACGGCGCCC	3
	3979	3	CCACACC GACGGCGCCC	3
	4236	4	CCACACC GACGGCGCCC	3
10	4242	4	CCACACC GACGGCGCCC	3
	3980	5	CCACACC GACGGCGCCC	3
	3985	7	CCACACC GACGGCGCCC	3
	3984	9	CCACACC GACGGCGCCC	3
	2570	17	CCACACC GACGGCGCCC	3

15 These oligonucleotides were characterized for hybridization efficiency as described in Example 6, ability to direct RNase H cleavage *in vitro* using mammalian RNase H as described in Example 8, and for antisense activity. Antisense activity against full length H-ras mRNA was 20 determined using a transient co-transfection reporter gene system in which H-ras gene expression was monitored using a ras-responsive enhancer element linked to the reporter gene luciferase, as described in Example 9.

Antisense activity of deoxy-gapped oligonucleotides
25 against full length ras mRNA: The beneficial properties of enhanced target affinity conferred by 2'-O-methyl modifications can be exploited for antisense inhibition provided these compounds are equipped with RNase H-sensitive deoxy gaps of the appropriate length. 2'-O-methyl deoxy gap 30 oligonucleotides were tested for antisense activity against

the full length H-ras mRNA using the H-ras transactivation reporter gene system described in Example 9. Antisense experiments were performed initially at a single oligonucleotide concentration (100 nM). Chimeric 2'-O-methyl 5 oligonucleotides containing deoxy gaps of five or more residues inhibited H-ras gene expression. The full deoxy compound gave approximately 50% inhibition. The fully 2'-O-methyl, 1-deoxy and 3-deoxy gave no inhibition. The 5-deoxy, 7-deoxy and 9-deoxy compounds gave approximately 85%, 95% and 10 90% inhibition, respectively. These compounds displayed activities greater than that of the full deoxy parent compound.

Dose response experiments were performed using these active compounds, along with the 2'-O-methyl chimeras 15 containing four deoxy residues. Oligonucleotide-mediated inhibition of full-length H-ras by these oligonucleotides was dose-dependent. The most active compound was the seven-residue deoxy chimera, which displayed an activity approximately five times greater than that of the full deoxy 20 oligonucleotide.

Shortened chimeric oligonucleotides: Enhanced target affinity conferred by the 2'-O-methyl modifications was found to confer activity on short chimeric oligonucleotides. A series of short 2'-O-methyl chimeric oligonucleotides were 25 tested for T_m and antisense activity vs. full length ras as described in Example 9. Table 4 shows T_m s for oligonucleotides 11, 13, 15 and 17 nucleotides in length, having deoxy gaps either 5 bases long or 7 bases long. In sharp contrast to the full deoxy 13-mer, both 2'-O-methyl 30 chimeric 13-mers inhibited ras expression, and one of the 11-mers was also active. This is shown in Figure 2.

TABLE 4

LENGTH	T _m (°C)	SEQUENCE	SEQ ID NO:
5	17	CCACACCGACGGCGCCC	3
	15	CACACCGACGGCGGCC	13
	13	ACACCGACGGCGC	12
	11	CACCGACGGCG	11
	17	CCACACCGACGGCGCCC	3
	15	CACACCGACGGCGGCC	13
10	13	ACACCGACGGCGC	12
	11	CACCGACGGCG	11

Relative antisense activity and ability to activate RNase H cleavage in vitro by chimeric 2'-O-methyl oligonucleotides is well correlated with deoxy length (Figure 3).

15 **Asymmetrical deoxy gaps:** It is not necessary that the deoxy gap be in the center of the chimeric molecule. It was found that chimeric molecules having the nucleotides of the region at one end modified at the 2' position to enhance binding and the remainder of the molecule unmodified (2'deoxy) 20 can still inhibit ras expression. Oligonucleotides of SEQ ID NO: 3 (17-mer complementary to mutant codon 12) in which a 7-deoxy gap was located at either the 5' or 3' side of the 17-mer, or at different sites within the middle of the molecule, all demonstrated RNase H activation and antisense activity. 25 However, a 5-base gap was found to be more sensitive to placement, as some gap positions rendered the duplex a poor activator of RNase H and a poor antisense inhibitor. Therefore, a 7-base deoxy gap is preferred.

Other sugar modifications: The effects of other 2' sugar 30 modifications besides 2'-O-methyl on antisense activity in chimeric oligonucleotides have been examined. These modifications are listed in Table 5, along with the T_m values

obtained when 17-mer oligonucleotides having 2'-modified nucleotides flanking a 7-base deoxy gap were hybridized with a 25-mer oligoribonucleotide complement as described in Example 6. A relationship was observed for these 5 oligonucleotides between alkyl length at the 2' position and T_m . As alkyl length increased, T_m decreased. The 2'-fluoro chimeric oligonucleotide displayed the highest T_m of the series.

TABLE 5

10 Correlation of T_m with Antisense Activity
2'-modified 17-mer with 7-deoxy gap
CCACACCGACGGCGCCC (SEQ ID NO: 3)

2' MODIFICATION	T_m (°C)	IC50 (nM)
Deoxy	64.2	150
O-Pentyl	68.5	150
O-Propyl	70.4	70
O-Methyl	74.7	20
Fluoro	76.9	10

These 2' modified oligonucleotides were tested for 20 antisense activity against H-ras using the transactivation reporter gene assay described in Example 9. As shown in Table 5, all of these 2' modified chimeric compounds inhibited ras expression, with the 2'-fluoro 7-deoxy-gap compound the most active. A 2'-fluoro chimeric oligonucleotide with a centered 25 5-deoxy gap was also active.

Chimeric phosphorothioate oligonucleotides having SEQ ID NO: 3 having 2'-O-propyl regions surrounding a 5-base or 7-base deoxy gap were compared to 2'-O-methyl chimeric oligonucleotides. ras expression in T24 cells was inhibited 30 by both 2'-O-methyl and 2'-O-propyl chimeric oligonucleotides with a 7-deoxy gap and a uniform phosphorothioate backbone.

When the deoxy gap was decreased to five nucleotides, only the 2'-O-methyl oligonucleotide inhibited ras expression.

Antisense oligonucleotide inhibition of H-ras gene expression in cancer cells: Two phosphorothioate 5 oligonucleotides (2502, 2503) complementary to the ras AUG region were tested as described in Example 10, along with chimeric oligonucleotides (4998, 5122) having the same sequence and 7-base deoxy gaps flanked by 2'-O-methyl regions. These chimeric oligonucleotides are shown in Table 6.

10

TABLE 6

Chimeric phosphorothioate oligonucleotides
having 2'-O-methyl ends (**bold**) and central deoxy gap
(AUG target)

15

OLIGO	# DEOXY	SEQUENCE	SEQ ID NO:
2502	20	CTTATATTCCGTATCGCTC	1
4998	7	CTTATATTCCGTATCGCTC	1
2503	20	TCCGTCATCGCTCCTCAGGG	2
5122	7	TCCGTCATCGCTCCTCAGGG	2

Compound 2503 inhibited ras expression in T24 cells by 20 71%, and the chimeric compound (4998) inhibited ras mRNA even further (84% inhibition). Compound 2502, also complementary to the AUG region, decreased ras RNA levels by 26% and the chimeric version of this oligonucleotide (5122) demonstrated 25 15% inhibition. Also included in this assay were two oligonucleotides targeted to the mutant codon 12. Compound 2570 (SEQ ID NO: 3) decreased ras RNA by 82% and the 2'-O-methyl chimeric version of this oligonucleotide with a seven-deoxy gap (3985) decreased ras RNA by 95%.

Oligonucleotides 2570 and 2503 were also tested to 30 determine their effects on ras expression in HeLa cells, which have a wild-type (i.e., not activated) H-ras codon 12. While

0022200-40555/950

both of these oligonucleotides inhibited ras expression in T24 cells (having activated codon 12), only the oligonucleotide (2503) specifically hybridizable with the ras AUG inhibited ras expression in HeLa cells. Oligonucleotide 2570 (SEQ ID NO: 3), specifically hybridizable with the activated codon 12, did not inhibit ras expression in HeLa cells, because these cells lack the activated codon-12 target.

Oligonucleotide 2570, a 17-mer phosphorothioate oligonucleotide complementary to the codon 12 region of activated H-ras, was tested for inhibition of ras expression (as described in Example 10) in T24 cells along with chimeric phosphorothioate 2'-O-methyl oligonucleotides 3980, 3985 and 3984, which have the same sequence as 2570 and have deoxy gaps of 5, 7 and 9 bases, respectively (shown in Table 3). The fully 2'-deoxy oligonucleotide 2570 and the three chimeric oligonucleotides decreased ras mRNA levels in T24 cells. Compounds 3985 (7-deoxy gap) and 3984 (9-deoxy gap) decreased ras mRNA by 81%; compound 3980 (5-deoxy gap) decreased ras mRNA by 61%. Chimeric oligonucleotides having this sequence, but having 2'-fluoro-modified nucleotides flanking a 5-deoxy (4689) or 7-deoxy (4690) gap, inhibited ras mRNA expression in T24 cells, with the 7-deoxy gap being preferred (82% inhibition, vs 63% inhibition for the 2'-fluoro chimera with a 5-deoxy gap).

25 Antisense oligonucleotide inhibition of proliferation of cancer cells: Three 17-mer oligonucleotides having the same sequence (SEQ ID NO: 3), complementary to the codon 12 region of activated ras, were tested for effects on T24 cancer cell proliferation as described in Example 11. 3985 has a 7-deoxy gap flanked by 2'-O-methyl nucleotides, and 4690 has a 7-deoxy gap flanked by 2'-F nucleotides (all are phosphorothioates). Effects of these oligonucleotides on cancer cell proliferation correlated well with their effects on ras mRNA expression shown by Northern blot analysis: oligonucleotide 2570 inhibited cell proliferation by 61%, the 2'-O-methyl chimeric

oligonucleotide 3985 inhibited cell proliferation by 82%, and the 2'-fluoro chimeric analog inhibited cell proliferation by 93%.

In dose-response studies of these oligonucleotides on 5 cell proliferation, the inhibition was shown to be dose-dependent in the 25 nM-100 nM range. IC₅₀ values of 44 nM, 61 nM and 98 nM could be assigned to oligonucleotides 4690, 3985 and 2570, respectively. The random oligonucleotide control had no effect at the doses tested.

10 The effect of ISIS 2570 on cell proliferation was cell type-specific. The inhibition of T24 cell proliferation by this oligonucleotide was four times as severe as the inhibition of HeLa cells by the same oligonucleotide (100 nM oligonucleotide concentration). ISIS 2570 is targeted to the 15 activated (mutant) ras codon 12, which is present in T24 but lacking in HeLa cells, which have the wild-type codon 12.

Chimeric backbone-modified oligonucleotides:
Oligonucleotides discussed in previous examples have had uniform phosphorothioate backbones. The 2'-modified chimeric 20 oligonucleotides discussed above are not active in uniform phosphodiester backbones. A chimeric oligonucleotide was synthesized (ISIS 4226) having 2'-O-methyl regions flanking a 5-nucleotide deoxy gap, with the gap region having a P=S backbone and the flanking regions having a P=O backbone. 25 Another chimeric oligonucleotide (ISIS 4223) having a P=O backbone in the gap and P=S in flanking regions was also made. These oligonucleotides are shown in Table 7.

Additional oligonucleotides were synthesized, completely 30 2'-deoxy and having phosphorothioate backbones containing either a single phosphodiester (ISIS 4248), two phosphodiesters (ISIS 4546), three phosphodiesters (ISIS 4551), four phosphodiesters (ISIS 4593), five phosphodiesters (ISIS 4606) or ten phosphodiester linkages (ISIS-4241) in the center of the molecule. These oligonucleotides are also shown 35 in Table 7.

TABLE 7

Chimeric backbone ($P=S/P=O$) oligonucleotides having 2'-O-methyl ends (**b**old) and central deoxy gap (backbone linkages indicated by s ($P=S$) or o ($P=O$))

OLIGO	P=S	SEQUENCE	SEQ ID NO:
10	2570	CsCsAsCsAsCsCsGsAsCsGsGsCsGsCsCsC	3
	4226	CoCoAoCoAoCsCsGsAsCsGoGoCoGoCoCoC	3
	4233	CsCsAsCsAsCoCoGoAoCoGsGsCsGsCsCsC	3
	4248	CsCsAsCsAsCsCsGsAoCsGsGsCsGsCsCsC	3
	4546	CsCsAsCsAsCsCsGsGoAoCsGsGsCsGsCsCsC	3
	4551	CsCsAsCsAsCsCsGoAoCoGsGsCsGsCsCsC	3
	4593	CsCsAsCsAsCsCoGoAoCoGsGsCsGsCsCsC	3
	4606	CsCsAsCsAsCsCoGoAoCoGoGsGsCsGsCsCsC	3
15	4241	CsCsAsCoAoCoCoGoAoCoGoGoCoGsGsCsCsC	3

Oligonucleotides were incubated in crude HeLa cellular extracts at 37°C to determine their sensitivity to nuclease degradation as described in Dignam et al., *Nucleic Acids Res.* 1983, 11, 1475-1489. The oligonucleotide (4233) with a five-
20 diester gap between phosphorothioate/2'-O-methyl wings had a $T_{1/2}$ of 7 hr. The oligonucleotide with a five-phosphorothioate gap in a phosphorothioate/2'-O-methyl molecule had a $T_{1/2}$ of 30 hours. In the set of oligonucleotides having one to ten
25 diester linkages, the oligonucleotide (4248) with a single phosphodiester linkage was as stable to nucleases as was the full-phosphorothioate molecule, ISIS 2570, showing no degradation after 5 hours in HeLa cell extract. Oligonucleotides with two-, three- and four-diester gaps had
30 $T_{1/2}$ of approximately 5.5 hours, 3.75 hours, and 3.2 hours, and oligonucleotides with five or ten deoxy linkages had $T_{1/2}$ of 1.75 hours and 0.9 hours, respectively.

B
6
5
4
3
2
1
0

Antisense activity of chimeric backbone-modified oligonucleotides: A uniform phosphorothioate backbone is not required for antisense activity. ISIS 4226 and ISIS 4233 were tested in the ras-luciferase reporter system for effect on ras expression as described in Examples 2-5, along with ISIS 2570 (fully phosphorothioate/all deoxy), ISIS 3980 (fully phosphorothioate, 2'-O-methyl wings with deoxy gap) and ISIS 3961 (fully phosphodiester, 2'-O-methyl wings with deoxy gap). All of the oligonucleotides having a P=S (i.e., nuclease-resistant) gap region inhibited ras expression. The two completely 2'deoxy oligonucleotides having phosphorothioate backbones containing either a single phosphodiester (ISIS 4248) or ten phosphodiester linkages (ISIS 4241) in the center of the molecule were also assayed for activity. The compound 15 containing a single P=O was just as active as a full P=S molecule, while the same compound containing ten P=O was completely inactive.

Chimeric phosphorothioate oligonucleotides of SEQ ID NO: 3 were made, having a phosphorothioate backbone in the 7-base 20 deoxy gap region only, and phosphodiester in the flanking regions, which were either 2'-O-methyl or 2'-O-propyl. The oligonucleotide with the 2'-O-propyl diester flanking regions was able to inhibit ras expression.

Inhibition of ras-luciferase gene expression by antisense oligonucleotides containing modified bases: A series 25 of antisense phosphorothioate oligonucleotides complementary to the codon-12 point mutation of activated ras were synthesized as described, having a 2-(amino)adenine at the position complementary to the uracil of the mutated codon 12. Because the amino group at the 2-position of the adenine is 30 able to hydrogen bond with the oxygen in the 2-position on the uracil, three hydrogen bonds instead of the usual two are formed. This serves to greatly stabilize the hybridization of the 2-(amino)adenine-modified antisense oligonucleotide to

the activated ras gene, while destabilizing or having no net effect on the stability of this oligonucleotide to the wild-type codon 12, because of the modified A-G mismatch at this position. This increases the specificity of the modified 5 oligonucleotide for the desired target.

An oligonucleotide having a single 2,-(diamino)adenosine at this position in an otherwise unmodified uniform phosphorothioate 17-mer (sequence identical to 2570, SEQ ID NO: 3) was found to be at least as effective an RNase H substrate as the 2570 sequence. It is therefore expected to be an effective antisense molecule. An oligonucleotide having a single 2,-(diamino)adenosine at this position in a deoxy gapped phosphorothioate oligonucleotide of the same sequence also demonstrates RNase H activation.

15 **In vivo anti-tumor data:** ISIS 2503 (SEQ ID NO: 2) has
been evaluated for activity against human tumors *in vivo* as
described in Examples 14 and 15. These studies employed a
human lung adenocarcinoma cell line (A549) which was
subcutaneously implanted into nude mice, resulting in tumor
20 growth at site of implantation. Since these cells do not
contain a mutation in the H-ras gene, but do express normal
H-ras, only the AUG-directed oligonucleotide ISIS 2503 was
evaluated for anti-tumor activity.

In the first study, phosphorothioate oligonucleotides
25 in saline were administered by intraperitoneal injection at
a dosage of 20 mg/kg. Drug treatment was initiated at the
time tumors first became visible (28 days following tumor cell
inoculation) and treatments were performed every other day.
As shown in Figure 4, no effect on tumor growth was observed
30 after treatment with the unrelated control phosphorothioate
oligonucleotide ISIS 1082 (SEQ ID NO: 55). However,
significant inhibition of tumor growth was observed for the
H-ras-specific oligonucleotide ISIS 2503 (SEQ ID NO: 2). The
anti-tumor effects of the H-ras compound were first observed

20 days following initiation of drug treatment and continued throughout the duration of the study.

In a related study, the anti-tumor activity of ISIS 2503 against MDA-MB-231 breast carcinoma tumors was investigated 5 as described in Example 14. These studies employed MDA-MB-231 tumors which were established by implanting cultured cells into the mammary fat pads of athymic nude mice. In these studies, phosphorothioate oligonucleotides formulated in saline, were administered daily by intraperitoneal injection 10 at dosages of 5, 10, and 25 mg/kg/day. Drug treatment was initiated at the time tumors first became visible. Tumor volume was calculated at days 4, 11 and 17 after tumor implantation and was measured at the maximum perpendicular diameter of the tumor. At day 4 the difference in tumor volume 15 between the vehicle treated animals and those of the high dose ISIS 2503 (25 mg/kg/day) treated animals was minimal, 25 mm³ and 45 mm³, respectively. However, at day 11 the vehicle treated tumors had grown to 60 mm³ while the ISIS 2503 treated animals had tumor volumes of 12 mm³ (both 10 and 25 mg/kg/day 20 doses) and 25 mm³ (5 mg/kg/day dose). At day 17, vehicle treated animals had tumor volumes of 175 mm³ while those treated with ISIS 2503 had tumor volumes of 13 mm³ (25 mg/kg/day dose), 20 mm³ (10 mg/kg/day dose) and 110 mm³ (5 mg/kg/day dose).

25 ISIS 2503 has also exhibited broad activity in other human tumor xenograft models including activity against tumors of mutant H-ras (MiaPaCa-2, pancreatic carcinoma cells), wild-type H-ras (MDA-MB-231, breast cancer cells, disclosed herein; HT-29 colon carcinoma cells) and unknown H-ras phenotypes 30 (Panc-1, pancreatic carcinoma cells; H-69, lung carcinoma cells).

In a second study, phosphorothioate oligonucleotides were prepared in a cationic lipid formulation (DMRIE:DOPE) and administered by subcutaneous injection as described in Example 35 15. Drug treatment was initiated one week following tumor

cell inoculation and was performed three times a week for only four weeks. As was observed in the first study, administration of the H-ras-specific compound ISIS 2503 (SEQ ID NO: 2) caused a marked reduction in tumor growth whereas the unrelated 5 control oligonucleotide (ISIS 1082) had no significant effect (Figure 5). Reduction in tumor volume was first observed 20 days following appearance of visible tumors and continued over time throughout the remainder of the study.

Stability of 2'-modified phosphodiester oligonucleotides

10 **in cells:** Modification of oligonucleotides to confer nuclease stability is required for antisense activity in cells. Certain modifications at the 2' position of the sugar have been found to confer nuclease resistance sufficient to elicit antisense effects in cells without any backbone modification. 15 A uniformly 2'-propoxy modified phosphodiester oligonucleotide (SEQ ID NO: 3) was found to inhibit H-ras expression in T24 cells, 24 hours after administration, at a level equivalent to a phosphorothioate 2'-deoxyoligonucleotide having the same sequence. Uniform 2'-methoxy phosphodiester oligonucleotide 20 also showed some activity. 2'-pentoxy modifications were found to be at least as active as the 2'-propoxy.

Antisense oligonucleotides active against Ki-ras:

Oligonucleotides were designed to be complementary to the 5'-untranslated region, 3'-untranslated region and 25 coding region of the human Ki-ras oncogene. McGrath, J.P. et al. *Nature* 1983, 304, 501-506. Of the latter, oligonucleotides were targeted to codons 12 and 61 which are known sites of mutation that lead to Ki-ras-mediated transformation, and also to codon 38, which is not known to 30 be involved in transformation. The oligonucleotides are shown in Table 8.

Table 8

Antisense Oligonucleotides Complementary to Human Ki-ras

	ISIS #	SEQUENCE	TARGET	SEQ ID NO:
5	6958	CTG CCT CCG CCG CCG CGG CC	5' UTR/5' cap	20
	6957	CAG TGC CTG CGC CGC GCT CG	5'-UTR	21
	6956	AGG CCT CTC TCC CGC ACC TG	5'-UTR	22
	6953	TTC AGT CAT TTT CAG CAG GC	AUG	23
10	6952	TTA TAT TCA GTC ATT TTC AG	AUG	24
	6951	CAA GTT TAT ATT CAG TCA TT	AUG	25
	6950	GCC TAC GCC ACC AGC TCC AAC	Codon 12 (WT)	26
	6949	CTA CGC CAC CAG CTC CA	Codon 12 (WT)	27
15	6948	G TAC TCC TCT TGA CCT GCT GT	Codon 61 (WT)	28
	6947	CCT GTA GGA ATC CTC TAT TGT	Codon 38	29
	6946	GGT AAT GCT AAA ACA AAT GC	3'-UTR	30
	6945	GGA ATA CTG GCA CTT CGA GG	3'-UTR	31
	7453	TAC GCC AAC AGC TCC	Codon 12 (G→T mut.)	32
	7679	TTT TCA GCA GGC CTC TCT CC	5'-UTR/AUG	33

Twelve Ki-ras-specific oligonucleotides were screened
 20 for antisense activity against three colon carcinoma cell
 lines that contain a mutation at codon 12 in the Ki-ras
 oncogene and evaluated by measurement of Ki-ras mRNA levels.
 As shown in Figure 6, half of the tested compounds displayed
 significant activity (at least 40% inhibition) against the Ki-
 25 ras transcript, with the most active compounds being targeted
 to the 5'- and 3'-untranslated regions. However, significant
 inhibition of Ki-ras expression was also observed for
 compounds directed against wild type codons 12 and 61.
 Compounds that displayed significant activity were effective
 30 against all three carcinoma cell lines tested.

003250-4555256

Dose response analysis of these compounds demonstrated that ISIS 6958 and ISIS 6957, both of which target the 5'-UTR, are the most potent inhibitors of Ki-ras in this series of oligonucleotides. These oligonucleotides were examined for 5 their ability to inhibit proliferation of Ki-ras transformed cell lines. The colon carcinoma cell line SW480 was treated with a single dose of oligonucleotide (200 nM) and cell number was determined over a five-day period. As shown in Figure 7 both Ki-ras specific oligonucleotides were effective 10 inhibitors of proliferation of SW480 cells, with ISIS 6957 (SEQ ID NO: 21) showing greater activity than ISIS 6958 (SEQ ID NO: 20). This difference in activity correlates well with the inhibition of Ki-ras mRNA expression (Figure 6).

Selectivity of inhibition of mutant Ki-ras relative to 15 normal Ki-ras: Oligonucleotides targeted to Ki-ras have been examined for their ability to selectively inhibit mutant Ki-ras relative to normal Ki-ras. Two cell lines were employed: the SW480 cell line that expresses mutant Ki-ras (codon 12, G to T transversion) and a cell line (HeLa) that expresses 20 normal Ki-ras. Two oligonucleotides were tested: ISIS 6957, SEQ ID NO: 21, a 20mer phosphorothioate targeted to the 5'-untranslated region of Ki-ras, and ISIS 7453, SEQ ID NO: 32, a 15mer phosphorothioate targeted to the Ki-ras codon 12 region. Ki-ras mRNA levels were measured 24 hours after 25 treatment. The codon 12-directed compound was effective in the cell line expressing mutant Ki-ras (87% inhibition vs. 18% inhibition in HeLa cells). However, the Ki-ras oligonucleotide targeted to the 5'-untranslated region was a potent inhibitor (95% inhibition) of Ki-ras expression in both 30 cell lines. Selectivity for mutant Ki-ras was found to be dependent on oligonucleotide concentration and affinity for the RNA target.

Ki-ras oligonucleotides with deoxy gaps: Phosphorothioate oligonucleotides (SEQ ID NO: 21, targeted to 35 the 5'-untranslated region of Ki-ras) were synthesized with

2'-O-methyl modifications flanking central 2'-deoxy gap regions of 6 or 8 nucleotides in length. Both gapped oligonucleotides were active against Ki-ras expression as determined by Northern blot analysis. A uniformly 2'-O-5 methylated compound (no deoxy gap) was inactive. An additional oligonucleotide, ISIS 7679 (SEQ ID NO: 33, complementary to the 5' untranslated/AUG region of Ki-ras), was also found to be active when synthesized with a 6- or 8-nucleotide deoxy gap.

10 **2'-Methoxyethoxy analogs of ISIS 2503 (H-ras):** A series of chimeric oligonucleotides were synthesized with the ISIS 2503 sequence (SEQ ID NO: 2) and various arrangements of 2'-methoxyethoxy (2'-MOE) modifications. These are shown in Table 9. All backbone linkages are phosphorothioates.

15

Table 9

2'-MOE analogs of ISIS 2503
Positions with 2'-MOE are shown in bold

ISIS #	Sequence (5'--3=)	SEQ ID NO:
13905	TCCGTCA T CGCTC C TCAGGG	2
20 13907	TCCGTCA T CG C T C TCAGGG	2
13909	TCCGTCA T CG C T C TCAGGG	2
13911	TCCGTCA T CG C T C TCAGGG	2
25 13917	TCCGTCA T CG C T C TCAGGG	2
13919	TCCGTCA T CG C T C TCAGGG	2
13920	TCCGTCA T CG C T C TCAGGG	2
13923	TCCGTCA T CG C T C TCAGGG	2
13926	TCCGTCA T CG C T C TCAGGG	2
25 13927	TCCGTCA T CG C T C TCAGGG	2

These oligonucleotides (except for 13919 and 13927 which have
30 not yet been tested) were tested for the ability to reduce H-ras mRNA levels in T24 cells as described in Example 10 except

that oligonucleotide and lipofectin were mixed in OptiMEM and kept at a constant ratio of 2.5ug/ml lipofectin per 100 nM oligonucleotide. All of the tested compounds had activity comparable to ISIS 2503, the parent compound, with IC50's of 5 50 nM or below. For this reason oligonucleotides containing one or more 2'-MOE modifications are preferred for reducing ras expression. Dose responses for these compounds are shown in Figure 8. ISIS 13177 (TCAGTAATAGCCCCACATGG; SEQ ID NO: 34) is a phosphorothioate oligodeoxynucleotide scrambled control 10 for SEQ ID NO: 2.

MMI analogs of ISIS 2503 (H-ras): A series of chimeric oligonucleotides were synthesized with the ISIS 2503 sequence (SEQ ID NO: 2) and various placements of methylene(methylimino)backbone linkages. These are shown in 15 Table 10. For ease of synthesis, dimers incorporating an MMI linkage were used in making these oligonucleotides. Dimers containing MMI backbone linkages are indicated by **bold** lettering. "o" indicates a phosphodiester linkage between MMI dimers. "s" indicates a phosphorothioate linkage between MMI 20 dimers. All unmarked linkages are phosphorothioates.

Table 10

MMI analogs of ISIS 2503

	ISIS #	Sequence (5'---3=)	SEQ ID NO:
25	14896	TCCGTCATCGCTCCTCAGGG	2
	14897	TC_oCGTCATCGCTCCTCAG_oGG	2
	14898	TC_sCGTCATCGCTCCTCAG_sGG	2
	14899	TC_oCG_oTCATCGCTCCTC_oA_oGGG	2
	14900	TC_sCG_sTCATCGCTCCTC_sAG_sAG	2

These compounds were tested for their ability to reduce H-ras 30 mRNA levels in T24 cells as described in Example 10 except that oligonucleotide and lipofectin were mixed in OptiMEM and

kept at a constant ratio of 2.5 μ g/ml lipofectin per 100 nM oligonucleotide. As shown in Figure 9, all of these compounds were able to reduce mRNA levels by 80% or more at doses of 500 nM and below. ISIS 13177 (SEQ ID NO: 34) is a 5 phosphorothioate oligodeoxynucleotide scrambled control for SEQ ID NO: 2. With the exception of ISIS 14899, all the MMI compounds were more active than the parent deoxyphosphorothioate compound, ISIS 2503. Several compounds (ISIS 14896, 14897, 14898) achieved nearly complete ablation 10 of ras mRNA. Oligonucleotides containing one or more MMI modifications are therefore highly preferred for reducing ras expression.

Antisense oligonucleotides active against N-ras:

A series of phosphorothioate oligodeoxynucleotides were 15 designed to target human N-ras using the published sequence (Genbank accession number HSNRASR, x02751). These compounds were tested for their ability to reduce N-ras levels in T24 cells as described in Example 10 except that the probe was an N-ras cDNA probe (purchased from Oncogene Science, Cambridge 20 MA; catalog no. HP129) and oligonucleotide and lipofectin were mixed in OptiMEM and kept at a constant ratio of 2.5 μ g/ml lipofectin per 100 nM oligonucleotide.

These oligonucleotides, and the percent reduction in N-ras mRNA demonstrated for each, are shown in Table 11. 25 Oligonucleotides shown in bold (SEQ ID NO: 44, 45, 46, 47, 49 and 52) demonstrated greater than 30% reduction of ras mRNA when screened at a 300 nM dose and are considered active in this assay. These sequences are therefore preferred. Of these oligonucleotides 14686, 14687, 14688, 14691 and 14694 30 (SEQ ID NO: 44, 45, 46, 49 and 52) showed greater than 50% inhibition. Dose response curves were obtained for oligonucleotides 14677, 14678, 14686, 14687, 14688, 14689, 14690, 14891, 14692, 14693, and 14694. These are shown in Figure 10. As can be seen from the figure, ISIS 14686 and

ISIS 14691 (SEQ ID NO: 44 and 49, respectively) gave nearly complete ablation of N-ras mRNA at a 400 nM dose.

Table 11

Oligonucleotides targeted to human N-ras

	ISIS #	Sequence (5'--3=)	Target Region	% Reduced	SEQ ID NO:
5	14677	CCGGGTCTAGAAGCTGCAG	5' UTR	0.0	35
	14678	TAAATCAGTAAAGAAACCG	5' UTR	0.0	36
	14679	GGACACAGTAACCAGCGGC	5' UTR	0.0	37
	14680	AACAGAACGCTACACCAAGGG	5' UTR	0.0	38
	14681	CAGACCCATCCATTCCGTG	5' UTR	0.0	39
	14682	GCCAAGAACATCAGACCCATC	5' UTR	0.0	40
	14683	AGGGGGAAAGATAAAACCGCC	5' UTR	0.0	41
	14684	CGCTTCCATTCTTCGCCAT	5' UTR	0.0	42
	14685	CCGCACCCAGACCCGCCCT	5' UTR	0.0	43
	14686	CAGCCCCCACCAAGGAGCGG	5' UTR	61.0	44
10	14687	GTCATTTCACACCAGCAAAGA	AUG	50.2	45
	14688	CAGTCATTTCACACCAGCAA	AUG	60.5	46
	14689	CTCAGTCATTTCACACCAGC	AUG	38.4	47
	14690	CGTGGGCTTGTTGTATCA	Coding	0.2	48
	14691	CCATACAAACCTGAGTCCC	3' UTR	58.3	49
15	14692	CAGACAGCCAAGTGAGGAGG	3' UTR	0.0	50
	14693	CCAGGGCAGAAAATAACAG	3' UTR	0.0	51
	14694	TTTGTGCTGTGGAAGAACCC	3' UTR	50.7	52
	14695	GCTATTAAATAACAATGCAC	3' UTR	0.0	53
	14696	ACTGATCACAGCTATTAAAT	3' UTR	0.0	54
20					
25					

The following examples illustrate the present invention and are not intended to limit the same.

EXAMPLES

Example 1 Synthesis and Characterization of Oligonucleotides

Unmodified oligodeoxynucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) 5 using standard phosphoramidite chemistry with oxidation by iodine. α -cyanoethyldiisopropyl-phosphoramidites are purchased from Applied Biosystems (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of $^3\text{H}-1,2-$ 10 benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 seconds and was followed by the capping step.

2'-methoxy oligonucleotides were synthesized using 2'- 15 methoxy α -cyanoethyldiisopropyl-phosphoramidites (Chemgenes, Needham, MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds. Other 2'-alkoxy oligonucleotides were synthesized by a modification of 20 this method, using appropriate 2'-modified amidites such as those available from Glen Research, Inc., Sterling, VA.

2'-fluoro oligonucleotides were synthesized as described in Kawasaki et al., *J. Med. Chem.* 1993, 36, 831-841. Briefly, the protected nucleoside N^6 -benzoyl-2'-deoxy-2'- 25 fluoroadenosine was synthesized utilizing commercially available 9- β -D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'- α -fluoro atom is introduced by a S_N2 -displacement of a 2'- β -O-trifyl group. Thus N^6 -benzoyl-9- β -D-arabinofuranosyladenine was 30 selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N^6 -benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-

dimethoxytrityl- (DMT) and 5'-DMT-3'-phosphoramidite intermediates.

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 5 9- β -D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. 10 Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished 15 by the modification of a known procedure in which 2, 2'-anhydro-1- β -D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3' phosphoramidites.

2'-deoxy-2'-fluorocytidine was synthesized via amination 20 of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N⁴-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3' phosphoramidites.

2'-(2-methoxyethyl)-modified amidites are synthesized 25 according to Martin, P., *Helv. Chim. Acta* 1995, 78,486-504. For ease of synthesis, the last nucleotide was a deoxynucleotide. 2'-O-CH₂CH₂OCH₃.cytosines may be 5-methyl cytosines.

Synthesis of 5-Methyl cytosine monomers:

30 **2,2'-Anhydro[1-(α -D-arabinofuranosyl)-5-methyluridine]:**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenyl-carbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated

to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether 5 (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 10 h) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield). The material was used as is for further reactions.

2'-O-Methoxyethyl-5-methyluridine:

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-15 methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The 20 residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. 25 The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product.

2'-O-Methoxyethyl-5'-0-dimethoxytrityl-5-methyluridine:

30 2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot 35 of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and

the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue 5 was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/-
10 Hexane/Acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-
15 uridine:**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at
20 room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with
25 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel
30 column and eluted using EtOAc/Hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine:

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the later solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

20 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine:

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine:

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO₄, and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite:

N⁴-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄, and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

5-methyl-2'-deoxycytidine (5-me-C) containing oligonucleotides were synthesized according to published methods (Sanghvi et al. *Nucl. Acids Res.* **1993**, 21, 3197-3203)

using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

Oligonucleotides having methylene(methylimino) (MMI) backbones are synthesized according to U.S. Patent 5,378,825, 5 which is coassigned to the assignee of the present invention and is incorporated herein in its entirety. For ease of synthesis, various nucleoside dimers containing MMI linkages were synthesized and incorporated into oligonucleotides. Other nitrogen-containing backbones are synthesized according 10 to WO 92/20823 which is also coassigned to the assignee of the present invention and incorporated herein in its entirety.

Oligonucleotides having amide backbones are synthesized according to De Mesmaeker et al. *Acc. Chem. Res.* 1995, 28, 366-374. The amide moiety is readily accessible by simple and 15 well-known synthetic methods and is compatible with the conditions required for solid phase synthesis of oligonucleotides.

Oligonucleotides with morpholino backbones are synthesized according to U.S. Patent 5,034,506 (Summerton and 20 Weller).

Peptide-nucleic acid (PNA) oligomers are synthesized according to P.E. Nielsen et al. *Science* 1991, 254, 1497).

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium 25 hydroxide at 55°C for 18 hours, the oligonucleotides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative 30 amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al. *J. Biol. Chem.* 1991, 266:18162-18171. Results obtained

with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 2 ras-Luciferase Reporter Gene Assembly

The ras-luciferase reporter genes described in this study were assembled using PCR technology. Oligonucleotide primers were synthesized for use as primers for PCR cloning of the 5'-regions of exon 1 of both the mutant (codon 12) and non-mutant (wild-type) human H-ras genes. The plasmids pT24-C3, containing the c-H-ras1 activated oncogene (codon 12, GGC→GTC), and pbc-N1, containing the c-H-ras proto-oncogene, were obtained from the American Type Culture Collection (Bethesda, MD). The plasmid pT3/T7 luc, containing the 1.9 kb firefly luciferase gene, was obtained from Clontech Laboratories (Palo Alto, CA). The oligonucleotide PCR primers were used in standard PCR reactions using mutant and non-mutant H-ras genes as templates. These primers produce a DNA product of 145 base pairs corresponding to sequences -53 to +65 (relative to the translational initiation site) of normal and mutant H-ras, flanked by NheI and HindIII restriction endonuclease sites. The PCR product was gel purified, precipitated, washed and resuspended in water using standard procedures.

PCR primers for the cloning of the *P. pyralis* (firefly) luciferase gene were designed such that the PCR product would code for the full-length luciferase protein with the exception of the amino-terminal methionine residue, which would be replaced with two amino acids, an amino-terminal lysine residue followed by a leucine residue. The oligonucleotide PCR primers used for the cloning of the luciferase gene were used in standard PCR reactions using a commercially available plasmid (pT3/T7-Luc) (Clontech), containing the luciferase reporter gene, as a template. These primers yield a product of approximately 1.9 kb corresponding to the luciferase gene, flanked by unique HindIII and BssHII restriction endonuclease

sites. This fragment was gel purified, precipitated, washed and resuspended in water using standard procedures.

To complete the assembly of the ras-luciferase fusion reporter gene, the ras and luciferase PCR products were 5 digested with the appropriate restriction endonucleases and cloned by three-part ligation into an expression vector containing the steroid-inducible mouse mammary tumor virus promotor MMTV using the restriction endonucleases NheI, HindIII and BssHII. The resulting clone results in the 10 insertion of H-ras 5' sequences (-53 to +65) fused in frame with the firefly luciferase gene. The resulting expression vector encodes a ras-luciferase fusion product which is expressed under control of the steroid-inducible MMTV promoter. These plasmid constructions contain sequences 15 encoding amino acids 1-22 of activated (RA2) or normal (RA4) H-ras proteins fused in frame with sequences coding for firefly luciferase. Translation initiation of the ras-luciferase fusion mRNA is dependent upon the natural H-ras AUG codon. Both mutant and normal H-ras luciferase fusion 20 constructions were confirmed by DNA sequence analysis using standard procedures.

Example 3 Transfection of Cells with Plasmid DNA

Transfections were performed as described by Greenberg, M.E., in *Current Protocols in Molecular Biology*, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY, with the following modifications. HeLa cells were plated on 60 mm dishes at 5×10^5 cells/dish. A total of 10 μ g or 12 μ g of DNA was added to each dish, of which 1 μ g was a vector expressing 25 the rat glucocorticoid receptor under control of the constitutive Rous sarcoma virus (RSV) promoter and the remainder was ras-luciferase reporter plasmid. Calcium phosphate-DNA coprecipitates were removed after 16-20 hours 30

by washing with Tris-buffered saline [50 mM Tris-Cl (pH 7.5), 150 mM NaCl] containing 3 mM EGTA. Fresh medium supplemented with 10% fetal bovine serum was then added to the cells. At this time, cells were pre-treated with antisense 5 oligonucleotides prior to activation of reporter gene expression by dexamethasone.

Example 4 Oligonucleotide Treatment of Cells

Following plasmid transfection, cells were washed with phosphate buffered saline prewarmed to 37°C and Opti-MEM 10 containing 5 μ g/mL N-[1-(2,3-dioleyloxy)propyl]-N,N,N,- trimethylammonium chloride (DOTMA) was added to each plate (1.0 ml per well). Oligonucleotides were added from 50 μ M stocks to each plate and incubated for 4 hours at 37°C. Medium was removed and replaced with DMEM containing 10% fetal 15 bovine serum and the appropriate oligonucleotide at the indicated concentrations and cells were incubated for an additional 2 hours at 37°C before reporter gene expression was activated by treatment of cells with dexamethasone to a final concentration of 0.2 μ M. Cells were harvested and assayed for 20 luciferase activity fifteen hours following dexamethasone stimulation.

Example 5 Luciferase Assays

Luciferase was extracted from cells by lysis with the detergent Triton X-100 as described by Greenberg, M.E., in 25 Current Protocols in Molecular Biology, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY. A Dynatech ML1000 luminometer was used to measure peak luminescence upon addition of luciferin (Sigma) to 625 μ M. For each extract, 30 luciferase assays were performed multiple times, using differing amounts of extract to ensure that the data were gathered in the linear range of the assay.

Example 6 Melting Curves

Absorbance vs temperature curves were measured at 260 nm using a Gilford 260 spectrophotometer interfaced to an IBM PC computer and a Gilford Response II spectrophotometer. The 5 buffer contained 100 mM Na⁺, 10 mM phosphate and 0.1 mM EDTA, pH 7. Oligonucleotide concentration was 4μM each strand determined from the absorbance at 85°C and extinction coefficients calculated according to Puglisi and Tinoco, *Methods in Enzymol.* 1989, 180, 304-325. T_m values, free 10 energies of duplex formation and association constants were obtained from fits of data to a two state model with linear sloping baselines. Petersheim, M. and Turner, D.H., *Biochemistry* 1983, 22, 256-263. Reported parameters are averages of at least three experiments. For some 15 oligonucleotides, free energies of duplex formation were also obtained from plots of T_m⁻¹ vs log₁₀ (concentration). Borer, P.N., Dengler, B., Tinoco, I., Jr., and Uhlenbeck, O.C., *J. Mol. Biol.*, 1974, 86, 843-853.

Example 7 Gel Shift Assay

20 The structured ras target transcript, a 47-nucleotide hairpin containing the mutated codon 12, was prepared and mapped as described in Lima et al., *Biochemistry* 1991, 31, 12055-12061. Hybridization reactions were prepared in 20μl containing 100 mM sodium, 10 mM phosphate, 0.1 mM EDTA, 100 25 CPM of T7-generated RNA (approximately 10 pM), and antisense oligonucleotide ranging in concentration from 1 pM to 10μM. Reactions were incubated 24 hours at 37°C. Following hybridization, loading buffer was added to the reactions and reaction products were resolved on 20% native polyacrylamide 30 gels, prepared using 45 mM tris-borate and 1 mM MgCl₂ (TBM). Electrophoresis was carried out at 10°C and gels were quantitated using a Molecular Dynamics Phosphorimager.

Example 8 RNase H Analysis

RNase H assays were performed using a chemically synthesized 25-base oligoribonucleotide corresponding to bases +23 to +47 of activated (codon 12, G→U) H-ras mRNA. The 5' end-labeled RNA was used at a concentration of 20 nM and incubated with a 10-fold molar excess of antisense oligonucleotide in a reaction containing 20 mM Tris-Cl, pH 7.5, 100 mM KCl, 10 mM MgCl₂, 1 mM dithiothreitol, 10µg tRNA and 4 U RNasin in a final volume of 10µl. The reaction components were preannealed at 37°C for 15 minutes then allowed to cool slowly to room temperature. HeLa cell nuclear extracts were used as a source of mammalian RNase H. Reactions were initiated by addition of 2µg of nuclear extract (5µl) and reactions were allowed to proceed for 10 minutes at 15 37°C. Reactions were stopped by phenol/chloroform extraction and RNA components were precipitated with ethanol. Equal CPMs were loaded on a 20% polyacrylamide gel containing 7M urea and RNA cleavage products were resolved and visualized by electrophoresis followed by autoradiography. Quantitation of 20 cleavage products was performed using a Molecular Dynamics Densitometer.

Example 9 ras Transactivation Reporter Gene System

The expression plasmid pSV2-oli, containing an activated (codon 12, GGC→GTC) H-ras cDNA insert under control of the 25 constitutive SV40 promoter, was a gift from Dr. Bruno Tocque (Rhone-Poulenc Sante, Vitry, France). This plasmid was used as a template to construct, by PCR, a H-ras expression plasmid under regulation of the steroid-inducible mouse mammary tumor virus (MMTV) promoter. To obtain H-ras coding sequences, the 30 570 bp coding region of the H-ras gene was amplified by PCR. The PCR primers were designed with unique restriction endonuclease sites in their 5'-regions to facilitate cloning. The PCR product containing the coding region of the H-ras

codon 12 mutant oncogene was gel purified, digested, and gel purified once again prior to cloning. This construction was completed by cloning the insert into the expression plasmid pMAMneo (Clontech Laboratories, CA).

- 5 The ras-responsive reporter gene pRDO53 was used to detect ras expression. Owen et al., *Proc. Natl. Acad. Sci. U.S.A.* 1990, 87, 3866-3870.

Example 10 Northern blot analysis of ras expression in vivo

The human urinary bladder cancer cell line T24 was obtained from the American Type Culture Collection (Rockville MD). Cells were grown in McCoy's 5A medium with L-glutamine (Gibco BRL, Gaithersburg MD), supplemented with 10% heat-inactivated fetal calf serum and 50 U/ml each of penicillin and streptomycin. Cells were seeded on 100 mm plates. When they reached 70% confluence, they were treated with oligonucleotide. Plates were washed with 10 ml prewarmed PBS and 5 ml of Opti-MEM reduced-serum medium containing 2.5 μ l DOTMA was added. Oligonucleotide was then added to the desired concentration. After 4 hours of treatment, the medium was replaced with McCoy's medium. Cells were harvested 48 hours after oligonucleotide treatment and RNA was isolated using a standard CsCl purification method. Kingston, R.E., in *Current Protocols in Molecular Biology*, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY.

The human epithelioid carcinoma cell line HeLa 229 was obtained from the American Type Culture Collection (Bethesda, MD). HeLa cells were maintained as monolayers on 6-well plates in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 100 U/ml penicillin. Treatment with oligonucleotide and isolation of RNA were essentially as described above for T24 cells.

Northern hybridization: 10 μ g of each RNA was electrophoresed on a 1.2% agarose/formaldehyde gel and transferred overnight to GeneBind 45 nylon membrane (Pharmacia LKB, Piscataway, NJ) using standard methods. Kingston, R.E., 5 in *Current Protocols in Molecular Biology*, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.), John Wiley and Sons, NY. RNA was UV-crosslinked to the membrane. Double-stranded 32 P-labeled probes were synthesized using the Prime a Gene labeling kit 10 (Promega, Madison WI). The ras probe was a Sali-NheI fragment of a cDNA clone of the activated (mutant) H-ras mRNA having a GGC-to-GTC mutation at codon-12. The control probe was G3PDH. Blots were prehybridized for 15 minutes at 68°C with the QuickHyb hybridization solution (Stratagene, La Jolla, 15 CA). The heat-denatured radioactive probe (2.5×10^6 counts/2 ml hybridization solution) mixed with 100 μ l of 10 mg/ml salmon sperm DNA was added and the membrane was hybridized for 1 hour at 68°C. The blots were washed twice for 15 minutes at room temperature in 2x SSC/0.1% SDS and once for 30 minutes at 60°C 20 with 0.1XSSC/0.1%SDS. Blots were autoradiographed and the intensity of signal was quantitated using an ImageQuant PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Northern blots were first hybridized with the ras probe, then stripped by boiling for 15 minutes in 0.1x SSC/0.1%SDS and rehybridized 25 with the control G3PDH probe to check for correct sample loading.

Example 11 Antisense oligonucleotide inhibition of proliferation of cancer cells

Cells were cultured and treated with oligonucleotide 30 essentially as described in Example 10. Cells were seeded on 60 mm plates and were treated with oligonucleotide in the presence of DOTMA when they reached 70% confluence.

Time course experiment: On day 1, cells were treated with a single dose of oligonucleotide at a final concentration of 100 nM. The growth medium was changed once on day 3 and cells were counted every day for 5 days, using a counting chamber. Dose-response experiment: Various concentrations of oligonucleotide (10, 25, 50, 100 or 250 nM) were added to the cells and cells were harvested and counted 3 days later. Oligonucleotides 2570, 3985 and 4690 were tested for effects on T24 cancer cell proliferation.

10 **Example 12 Synthesis of 2-(amino)adenine-substituted
oligonucleotides**

Oligonucleotides are synthesized as in Example 1, with the following exception: at positions at which a 2-(amino)adenine is desired, the standard phosphoramidite is replaced with a commercially available 2-aminodeoxyadenosine phosphoramidite (Chemgenes).

Example 13 Culture of A549 cells

A549 cells (obtained from the American Type Culture Collection, Bethesda MD) were grown to confluence in 6-well plates (Falcon Labware, Lincoln Park, NJ) in Dulbecco's modified Eagle's medium (DME) containing 1 g glucose/liter and 10% fetal calf serum (FCS, Irvine Scientific, Santa Ana, CA).

25 **Example 14 Oligonucleotide treatment of human tumor
cells in nude mice - intraperitoneal
injection**

Human lung carcinoma A549 cells were harvested and 5 x 10⁶ cells (200μl) were injected subcutaneously into the inner thigh of nude mice. Palpable tumors develop in approximately one month. Phosphorothioate oligonucleotides ISIS 2503 and 30 1082 (unrelated control) were administered to mice intraperitoneally at a dosage of 20 mg/kg body weight, every

other day for approximately ten weeks. Mice were monitored for tumor growth during this time.

Human breast carcinoma MDA-MB-231 cells were harvested and 5×10^6 cells (200 μ l) were injected subcutaneously into 5 the mammary fat pads of athymic nude mice. Palpable tumors develop in approximately one month. Phosphorothioate oligonucleotides ISIS 2503 and a vehicle containing no oligonucleotide were administered to mice intraperitoneally at a dosages of 5, 10, and 25 mg/kg/day body weight, every day 10 for approximately 20 days. Mice were monitored for tumor growth during this time.

Example 15 Oligonucleotide treatment of human tumor cells in nude mice - subcutaneous injection with cationic lipid

15 Human lung carcinoma A549 cells were harvested and 5×10^6 cells (200 μ l) were injected subcutaneously into the inner thigh of nude mice. Palpable tumors develop in approximately one month. Phosphorothioate oligonucleotides ISIS 2503 and the unrelated control oligonucleotide 1082 (dosage 5 mg/kg), 20 prepared in a cationic lipid formulation (DMRIE/DOPE, 60 mg/kg) were administered to mice subcutaneously at the tumor site. Drug treatment began one week following tumor cell inoculation and was given twice a week for only four weeks. Mice were monitored for tumor growth for a total of nine 25 weeks.

Example 16 Stability of 2' modified oligonucleotides in T24 cells

T24 bladder cancer cells were grown as described in Example 10. Cells were treated with a single dose (1 μ M) of 30 oligonucleotide and assayed for H-ras mRNA expression by Northern blot analysis 24 hours later. Oligonucleotides

tested were analogs of ISIS 2570 (SEQ ID NO: 3), a 17mer targeted to H-ras codon 12.

Example 17 Activity of Ki-ras oligonucleotides against three colon carcinoma cell lines

5 Human colon carcinoma cell lines Calu 1, SW480 and SW620 were obtained from the American Type Culture Collection (ATCC) and cultured and maintained as described for HeLa cells in Example 10. Cells were treated with a single dose of oligonucleotide (200 mM) and Ki-ras mRNA expression was
10 measured by Northern blot analysis 24 hours later. For proliferation studies, cells were treated with a single dose of oligonucleotide (200 nM) at day zero and cell number was monitored over a five-day period.

**Example 18 Oligonucleotide inhibition of mutant vs.
15 wild-type Ki-ras**

SW480 cells were cultured as in the previous example. HeLa cells were cultured as in Example 10. Cells were treated with a single dose (100 nM) of oligonucleotide and mRNA levels were determined by Northern blot analysis 24 hours later.

20 Example 19 Effects of antisense inhibition of H-ras on patients with advanced cancer-24 hour weekly infusion

Nineteen fully evaluable patients with a range of cancer types including colorectal (9) sarcoma (4) and other (6; one
25 each breast, NSCLC (non-small cell lung carcinoma), renal, melanoma, bladder and unknown) received ISIS 2503 by a 24 hour weekly infusion for up to nine doses of 3, 6, 12, 18 and 24 mg/kg/wk for three weeks. A single dose escalation to the next dose level was permitted for stable or responding
30 patients. There were ten men and nine women with a median age of 61 (range 44-69) and a median ECOG Performance Status (PS)

of 1 (range 0-2). ISIS 2503 infusion was well tolerated. Eligibility required an ECOG PS of \leq 2 and histologically confirmed cancer with measurable or evaluable disease and no effective therapy. Normal organ function was also required
5 (creatinine \leq 1.5 mg/dL; bilirubin \leq 1.5 mg/dL; AST/ALT < 2.5 X Upper limit of normal detection (ULN); ANC > 1500 cells/ μ l; platelet count > 100,000/ μ L; hemoglobin > 9 g/dL and prothrombin time/activated partial thromboplastin (PT/aPTT) \leq ULN). Patients also had no underlying disease state
10 associated with active bleeding nor were they on any anti-coagulation therapy or had any history of brain or CNS metastases. All patients were treated for three cycles (9 weeks) at doses of 3 (1 patient), 6 (3 patients; 1 patient escalated to the 12 mg/kg dose), 12 (3 patients), 18 (6
15 patients) and 24 (7 patients) mg/kg/wk prior to response assessment.

Clinical responses in patients with advanced cancer-24 hour weekly infusion

20 Pharmacokinetic studies demonstrated a dose-related increase in plasma concentrations with steady-state concentrations of 2.03, 3.95, 8.84 and 14.83 μ g/ml for the 4 doses studied. Approximately 65% of the drug is intact at 24 hours at all doses. Serological evidence of complement activation was observed at the end of the infusion, but no clinical evidence of complement activation was apparent. Dose limiting toxicity was observed at a 24/mg/kg/wk dose level and consisted of one patient with acute renal failure and one with transient renal insufficiency and grade 3 hyperbilirubinemia.
25 The dose limiting toxicity only occurred, however, at the first dose of ISIS 2503 and no recurrent or cumulative toxicity was seen. Three patients developed a syndrome associated with their first infusion characterized by an increase creatinine and anemia with evidence of
30 microangiopathy in 2 of the 3 cases. In two of the cases, the
35

toxicity was self-limiting and rapidly resolved in 3-7 days. The third episode proceeded to acute renal failure and the patient expired from progressive cancer on dialysis. Dose escalation was stopped at the 24 mg/kg/wk dose level due to 5 two such events. Eighteen mg/kg/wk was determined to be the maximal tolerable dose. At doses > 6 mg/kg, grade 1-2 post-infusion fevers were seen. These were managed with acetaminophen and/or NSAIDS. One patient with a grade 2 allergic rash at the 18 mg/kg dose level and this patient was 10 not re-challenged. Transient grade 1 thrombocytopenia was seen in several patients treated at the higher doses. One patient developed a grade 3 thrombocytopenia coincident with her rapidly reversible renal insufficiency. No objective responses have been seen, though one patient with melanoma had 15 stable disease at 9 weeks and continued on therapy. She experienced a minor response with shrinkage of liver metastases. She continued on the therapy with stable disease/minor response for 9 cycles (27 weeks) until developing brain metastases. Nine patients experienced 20 progression of disease. The remaining patients were not evaluable for response due to early withdrawal. In conclusion, ISIS 2503 can be safely administered via a weekly 24 hour continuous intravenous infusion at doses of ≤ 18 mg/kg/wk.

Example 20 Effects of antisense inhibition of H-ras on
25 patients with advanced cancer-14 day
 continuous infusion (ISIS 2503-CS1)

A continuous intravenous infusion of ISIS 2503 was administered to 23 evaluable patients (9 male, 14 female; age 30 range 39-74 years) at doses of 1.0 (3 patients), 2.0 (3 patients), 3.0 (3 patients), 4.5 (3 patients), 6.0 (3 patients), 8.0 (3 patients) and 10.0 (4 patients) mg/kg/d by 14-day continuous infusion, repeated every 21 days. A single

patient was studied at lower doses and shorter treatment durations to guard against early toxicity related to suppression of H-ras expression. This patient received 0.5-1.0 mg/kg/d of ISIS 2503. Subsequently, patients received 69 cycles of ISIS 2503 and no dose-limiting toxicities were observed.

Eligibility required an ECOG PS of \leq 2 and histologically confirmed cancer with measurable or evaluable solid tumor or lymphoma and no effective therapy. Normal organ function was also required (creatinine \leq 1.5 mg/dL; bilirubin \leq 2.0 mg/dL; AST/ALT $<$ 2.5x ULN (\leq 5x in the presence of hepatic metastasis); ANC $>$ 1500/mm³; platelet count $>$ 100,000/mm³; hemoglobin $>$ 9 g/dL and prothrombin time/activated partial thromboplastin (PT/aPTT) normal). Patients also had no underlying disease state associated with active bleeding nor were they on any anti-coagulation therapy or had any uncontrolled CNS involvement by tumor. Pregnant women were also excluded. Endpoints involved the measure of toxicity National Cancer Institute-Common Toxicity Criteria (NCI-CTC), tumor response, pharmacokinetics and H-ras mRNA expression in peripheral blood mononuclear cells.

ISIS 2503 was supplied as a sterile solution in 1 ml or 10 ml vials containing phosphate buffered saline (pH 7.4) at a concentration of 10 mg/ml. Prior to administration ISIS 2503 was diluted in normal saline for infusion by a volumetric infusion pump with a 0.22 μ m in-line filter.

Patient characteristics included three patients with colon, renal and liposarcoma tumors, treated for 2, 2, and 11 cycles, respectively; three patients with ovarian, mesothelioma and colon tumors, treated for 2, 6, and 2 cycles, respectively; three patients with pancreas, ovarian, and breast tumors, treated for 2, 2, and 2 cycles, respectively; three patients with colon, colon, and non-Hodgkin's lymphoma tumors, treated for 8, 2, and 2 cycles, respectively; three patients with ovarian, colon and colon, tumors, treated for

2, 2, and 2 cycles, respectively; three patients with bladder, colon and pancreatic tumors, treated for 2, 2, and 9 cycles, respectively; and four patients with non-small cell lung carcinoma, hepatoma, non-small cell lung carcinoma and renal 5 tumors, treated for 1, 2, 2, and 2 cycles, respectively.

Clinical responses in patients with advanced cancer-14 day continuous infusion

The toxicity of ISIS 2503 in this study was limited to 10 grade 1-2 fever (10 mg/kg, 2 patients), grade 2 fatigue (10 mg/kg, 2 patients; 4.5 mg/kg, 1 patient) and grade 2 nausea (6 mg/kg, 2 patients). There were no complete or partial responses; 4 patients (liposarcoma, 1.0 mg/kg; mesothelioma, 2.0 mg/kg; colon, 4.5 mg/kg; pancreatic, 8 mg/kg) had stable 15 disease for 10, 6, 8 and 9 cycles, respectively. Preliminary pharmacokinetic analysis demonstrated dose-related increases in steady-state plasma levels of intact ISIS 2503, with levels of 2.22 ± 0.99 ug/ml (approximately 320 ± 140 nM) at the 4.5 mg/kg dose level. Across the dose range 2.0-4.5 mg/kg, the 20 plasma concentrations revealed that 63-68% of ISIS 2503 remained intact.

The best tumor responses were seen in four patients; one with sarcoma (pelvic masses) wherein stable disease was achieved after 10 cycles at 1.0 mg/kg/d with prior MAID 25 (mesna, doxorubicin, ifosfamide and DTIC) chemotherapy; one with mesothelioma (measurable disease) wherein stable disease was achieved and continued after 4 cycles at 2.0 mg/kg/d with progression after 6 cycles with no prior therapy; one with colon cancer wherein stable disease was achieved after 6 30 cycles at 4.5 mg/kg/d with progression after 8 cycles, patient having prior surgery and adjuvant 5-Flurouracil + RT; and one patient with pancreatic cancer wherein stable disease was achieved after 8 cycles at 8.0 mg/kg/d but was removed from the study due to hepatic abscess after cycle 9. Progression

in the last patient followed prior 5-Fluorouracil + RT with further progression following prior gemcitabine treatment.

Example 21 Reduction of H-ras expression in peripheral blood mononuclear cells of cancer patients
5 after treatment with antisense oligonucleotide-14 day continuous infusion

Patient peripheral-blood mononuclear cells (PBMCs) were analyzed for H-ras mRNA levels after treatment via 14-day continuous intravenous infusion through two cycles.

10 Granulocytes and lymphocytes were separated by density gradient centrifugation of whole blood. Cells were lysed in guanidinium solution, and RNA was isolated by step gradient centrifugation of the cell lysate over 5.7M CsCl. Total cellular RNA was separated on a 1.2% agarose gel and 15 transferred from the gel to a blotting membrane by overnight capillary action. Membranes with bound RNA were hybridized with a random-primed, ³²P-labeled RNA probe made using a human H-ras cDNA template. Membranes were washed, and H-ras mRNA was visualized and quantitated by phosphorimage analysis.
20 Results were expressed as a percentage of pre-treatment levels. Reduction of H-ras expression by 20% was seen in 4 out of 6 patients by day 7 in the first cycle and by 30% in 5 out of 6 patients by day 14. In the second cycle reductions of up to 70% were seen in 5 out of 6 patients at day 7 and up to 25 80% at day 14. Reduced H-ras mRNA expression was observed by Northern blot at both the 1.0 and 2.0 mg/kg dose level.

Example 22 Effects of antisense inhibition of H-ras as first-line therapy in patients with advanced colorectal carcinoma-14 day continuous infusion
30

A continuous intravenous infusion of ISIS 2503 was administered to 17 evaluable patients with previously

20230414-15569

untreated stage IV or recurrent colorectal carcinoma (11 male, 6 female; age range 46-81 years) at a dose of 6.0 mg/kg/d by 14-day continuous infusion, repeated every 21 days. These patients received 38 cycles and were evaluated for tumor response after every 3 treatment cycles. Treatment continued until disease progression in patients with objective response or stable disease. Eligibility required an ECOG PS of \leq 2 and histologically confirmed cancer with measurable or evaluable solid tumor or lymphoma and no effective therapy. Normal organ function was also required (creatinine \leq 1.5 mg/dL; bilirubin \leq 2.0 mg/dL; AST/ALT $<$ 2.5x ULN (\leq 5x in the presence of hepatic metastasis); ANC $>$ 1500/mm³; platelet count $>$ 100,000/mm³; hemoglobin $>$ 9 g/dL and prothrombin time/activated partial thromboplastin (PT/aPTT) normal). Patients also had no underlying disease state associated with active bleeding nor were they on any anti-coagulation therapy or had any uncontrolled CNS involvement by tumor. Pregnant women were also excluded.

ISIS 2503 was supplied as a sterile solution in 1 ml or 20 10 ml vials containing phosphate buffered saline (pH 7.4) at a concentration of 10 mg/ml. Prior to administration ISIS 2503 was diluted in normal saline for infusion by a volumetric infusion pump with a 0.22 μ m in-line filter.

25 Clinical responses in patients with advanced colorectal carcinoma-14 day continuous infusion

Toxicity of ISIS 2503 was limited to grade 1-2 fever in the first 24-48 hours after starting the infusion in several patients, and grade 1 thrombocytopenia in 3 patients. The best responses to date are; stable disease, 2 patients (6 and 3 cycles); progressive disease, 5 patients; and too early, 5 patients. Five patients were not evaluable for response. ISIS 2503 was well tolerated at this dose and schedule in patients with advanced colorectal cancer.

Accrual is continuing to estimate the activity of single-agent ISIS 2503 in this patient population.

002250-4957550

What is claimed is:

1. An oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human ras and which is capable of inhibiting ras expression.
- 5 2. The oligonucleotide of claim 1 which is targeted to mRNA encoding human H-ras.
3. The oligonucleotide of claim 1 which is targeted to mRNA encoding human Ki-ras.
4. The oligonucleotide of claim 1 which is targeted 10 to mRNA encoding human N-ras.
5. The oligonucleotide of claim 4 which is targeted to a 5' untranslated region, translation initiation site, coding region or 3' untranslated region of an mRNA encoding human N-ras.
- 15 6. The oligonucleotide of claim 4 which has SEQ ID NO: 44, 45, 46, 47, 49 or 52.
7. The oligonucleotide of claim 1 which comprises at least one backbone modification.
8. The oligonucleotide of claim 1 wherein at least one 20 of the nucleotide units of the oligonucleotide is modified at the 2' position of the sugar.
9. The oligonucleotide of claim 1 which is a chimeric oligonucleotide.
10. The oligonucleotide of claim 1 in a 25 pharmaceutically acceptable carrier.

11. A method of modulating the expression of human ras comprising contacting tissues or cells containing a human ras gene with an effective amount of an oligonucleotide of claim 1, whereby expression of ras is modulated.

5 12. A method of inhibiting the proliferation of cancer cells comprising contacting cancer cells with an effective amount of an oligonucleotide of claim 1, whereby proliferation of the cancer cells is inhibited.

10 13. A method of preventing or treating a condition arising from the activation of a ras oncogene comprising contacting an animal suspected of having a condition arising from the activation of a ras oncogene with an effective amount of an oligonucleotide of claim 1, whereby said condition is prevented or treated.

15 14. The method of claim 13 wherein said activation of a ras oncogene is abnormal expression of a ras oncogene.

15. The method of claim 13 wherein said condition is a hyperproliferative condition.

20 16. The method of claim 13 wherein the condition is cancer.

17. The method of claim 13 wherein the condition is colorectal cancer, melanoma, liposarcoma, mesothelioma, sarcoma, colon cancer, or pancreatic cancer.

25 18. The method of claim 11 wherein the cells are cancer cells.

19. The method of claim 11 wherein the cells are blood cells.

20. The method of claim 11 wherein the cells are peripheral blood mononuclear cells.

21. A method of reducing expression of a preselected mRNA target in blood cells of a subject, comprising
5 administering to said subject an oligonucleotide targeted to said preselected mRNA in an amount sufficient to reduce expression of said mRNA target.

22. The method of claim 21 wherein the blood cells are peripheral blood mononuclear cells.

10 23. The method of claim 21 wherein said preselected mRNA target is H-ras.

002252-4550/560

ABSTRACT

Compositions and methods are provided for the modulation of ras expression. Oligonucleotides are provided which are targeted to nucleic acids encoding human ras.

5 Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using

10 the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions, or particular cancers, associated with ras are also disclosed.

002250-000256

Fig. 1a




Fig. 1b




Fig. 1c




Fig. 1d




Fig. 1e





Fig. 1f






Fig. 1g




Fig. 1h




Fig. 2

002250°45552560




Fig. 3




Fig. 4




Fig. 5

032268-4552550




Fig. 6

002250 * 452200




Fig. 7





Fig. 8

Fig. 9






Fig. 10

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: **ANTISENSE OLIGONUCLEOTIDE INHIBITION OF RAS** the specification of which:

(xx) is attached hereto.

() was filed on _____ as Application Serial No. _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed		
			Yes	No	
			Yes	No	
			Yes	No	
			Yes	No	

00251450

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented)
09/128,494	August 3, 1998	pending
08/411,734	April 3, 1995	pending
PCT/US93/09346	October 1, 1993	
08/007,996	January 21, 1993	abandoned
07/958,134	October 5, 1992	abandoned

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **Jane Massey Licata**, Registration No. 32,257, and **Kathleen A. Tyrrell**, Registration No. 38,350 of the firm of **Law Offices of Jane Massey Licata**, 66 East Main Street, Marlton, New Jersey 08053, and

Address all telephone calls and correspondence to:

Jane Massey Licata, Esq.
Law Offices of Jane Massey Licata
66 East Main Street
Marlton, New Jersey 08053

Telephone No.: (856) 810-1515

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or

imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name: Brett P. Monia	Inventor's Signature:	Date:
	Residence: 7605 Nueva Castilla Way, LaCosta, CA 92009	Citizenship: USA	
Post Office Address: Same as above.			
2	Full Name: Lex M. Cowsert	Inventor's Signature:	Date
	Residence: 3008 Newshire Street, Carlsbad, CA 92008	Citizenship: USA	
Post Office Address: Same as above.			
3	Full Name: Muthiah Manoharan	Inventor's Signature:	Date
	Residence: 7634 Reposada Drive, Carlsbad, CA 92009	Citizenship:USA	
Post Office Address: Same as above.			
4	Full Name:	Inventor's Signature:	Date
	Residence:	Citizenship:	
Post Office Address: Same as above.			

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Monia, B.P., Cowser, L.M. and Manoharan, M.
- (ii) TITLE OF INVENTION: Antisense Oligonucleotide Inhibition of ras
- (iii) NUMBER OF SEQUENCES: 55

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Jane Massey Licata
- (B) STREET: 66 East Main Street
- (C) CITY: Marlton
- (D) STATE: NJ
- (E) COUNTRY: USA
- (F) ZIP: 08053

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
- (B) COMPUTER: IBM COMPATIBLE
- (C) OPERATING SYSTEM: WINDOWS 95
- (D) SOFTWARE: WORDPERFECT 6.1 for WINDOWS

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: not assigned
- (B) FILING DATE: herewith
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA 1:

- (A) APPLICATION NUMBER: 09/128,494
- (B) FILING DATE: August 3, 1998

(viii) PRIOR APPLICATION DATA 2:

- (A) APPLICATION NUMBER: 08/411,734
- (B) FILING DATE: April 3, 1995

(ix) PRIOR APPLICATION DATA 3:

- (A) APPLICATION NUMBER: PCT/US93/09346
- (B) FILING DATE: October 1, 1993

- 052250-TMSS/CS60
- (vii) PRIOR APPLICATION DATA 4:
- (A) APPLICATION NUMBER: 07/958,134
- (B) FILING DATE: October 5, 1992
- (viii) PRIOR APPLICATION DATA 5:
- (A) APPLICATION NUMBER: 08/007,996
- (B) FILING DATE: January 21, 1993
- (ix) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Jane Massey Licata
- (B) REGISTRATION NUMBER: 32,257
- (C) REFERENCE/DOCKET NUMBER: ISPH-0463
- (x) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (856) 810-1515
- (B) TELEFAX: (856) 810-1454
- (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear
- (iv) ANTI-SENSE: Yes
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTTATATTCC GTCATCGCTC

20

- (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
TCCGTCATCG CTCCTCAGGG

20

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
CCACACCGAC GGCCCC

17

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
CCCACACCGA CGGCGCCC

19

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

DNA 5' TCGCTCCTCA

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCCCCACACCG ACGGGCGCCCA C

21

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TGCCCCACACC GACGGCGCCC ACC

23

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TATTCCGTCA TCGCTCCTCA

20

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CGACG

5

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CCGACGG

7

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

ACCGACGGC

9

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

5

3723504505/550

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CACCGACGGC G

11

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

ACACCGACGG CGC

13

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CACACCGACG GCGCC

15

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CCACACCGAC GGCGCC

16

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CACACCGACG GCGCCC

16

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CCCACACCGA CGGCGCCC

18

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
CCACACCGAC GGCGCCCA

18

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
TGGCCCACAC CGACGGCGCC CACCA

25

(2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
CCACACCGCC GGCGCCC

17

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20
CTGCCTCCGC CGCCGCGGCC

20

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
CAGTGCCTGC GCCGCGCTCG

20

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
- (iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
AGGCCTCTCT CCCGCACCTG

20

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
TTCAGTCATT TTCAGCAGG

20

(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
TTATATTCAG TCATTTTCAG

20

(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
CAAGTTTATA TTCAGTCATT

20

(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

DRAFT - 4560

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GCCTACGCCA CCAGCTCAA C

21

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

CTACGCCACC AGCTCCA

17

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GTACTCCCT TGACCTGCTG T

21

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

11

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

CCTGTAGGAA TCCTCTATTG T

21

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

GGTAATGCTA AAACAAATGC

20

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GGAATACTGG CACTTCGAGG

20

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

12

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
TACGCCAAC GCTCC

15

(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:
TTTCAGCAG GCCTCTCTCC

20

(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
TCAGTAATAG CCCCACATGG

20

(2) INFORMATION FOR SEQ ID NO: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

13

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
CGGGTCCCTA GAAGCTGCAG

20

(2) INFORMATION FOR SEQ ID NO: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:
TAAATCACTA AAAGAAAACCG

20

(2) INFORMATION FOR SEQ ID NO: 37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:
GGACACAGTA ACCAGGCGGC

20

(2) INFORMATION FOR SEQ ID NO: 38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:
AACAGAAAGCT ACACCAAGGG

20

(2) INFORMATION FOR SEQ ID NO: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:
CAGACCCATC CATTCCCGTG

20

(2) INFORMATION FOR SEQ ID NO: 40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:
GCCAAGAAAT CAGACCCATC

20

(2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

00220045557650

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

AGGGGGAAGA TAAAACCGCC

20

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

CGCTTCCATT CTTTCGCCAT

20

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

CCGCACCCAG ACCCGCCCT

20

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:
CAGCCCCCAC CAAGGAGCGG

20

(2) INFORMATION FOR SEQ ID NO: 45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:
GTCATTTCAC ACCAGCAAGA

20

(2) INFORMATION FOR SEQ ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(iv) ANTI-SENSE: Yes
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:
CAGTCATTTAC ACACCAGCAA

20

(2) INFORMATION FOR SEQ ID NO: 47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

CTCAGTCATT TCACACCAGC

20

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

CGTGGGCTTG TTTGTATCA

20

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

CCATACAACC CTGAGTCCCA

20

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

002360+1555496

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

CAGACAGCCA AGTGAGGAGG

20

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

CCAGGGCAGA AAAATAACAG

20

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

TTTGTGCTGT GGAAGAACCC

20

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic Acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

GCTATTAAAT ACAATGCAC

20

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

ACTGATCACA GCTATTAAAT

20

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

GCCGAGGTCC ATGTCGTACG C

21